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Figure 1: The Systems Biology view of life states that insights into the logic of cellular 
organization can be achieved when the cell is studied considering the universal organizing 
principles of complex networks, in which the components, unique to a given organism, are 
connected by functional links. Partially reproduced with permission from [21]. 
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Figure 2: Approaches to complex diseases in network medicine.?
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?
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Figure 3: The holistic approach of system medicine prompts the need for multilevel integration 
of heterogeneous patient information generated by different data sources, namely: 
environmental, clinical, biological and genetic data.?
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Figure 4: The Synergy-COPD translational research design. 
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Figure 5: Synergy-COPD framework that links data and models, establishing the key link 
between basic low-level observable physiological or biological parameters (such as protein 
concentrations, CT scan image or inspired PO2) and high-level unobservable outputs (such as 
a subtype of COPD, disease progression, etc.). In the generic sense, mechanistic models (M1 
to M3 in the figure) are used to study the values of some entities; while probabilistic models 
(P1 and P2) are key linking patient-specific measures and predictions. Specific implementation 
of this framework depend in the different biological question of we aim to address. 
?
????????? ??? ???? ?????????? ???????? ???????? ????????? ???? ???????????? ??????????
??????????????? ???????????????????????? ????????????????????????????????????????????
???? ????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
??????????? ??? ??? ??????????? ??? ?????????? ??????????? ??? ???? ???????????? ??????? ??????
??????????????????????? ????????????????????????????????????????????????????????????????
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 21 
 
 
?????? ? ????? ??? ???? ????????? ?????????? ??? ???? ???????????? ????????? ??????
????????????? ??? ??????????? ????? ?????????????? ???? ??????????? ??? ?????????????
?????????????????????????????????
???? ?????? ???? ???????? ???? ???? ?? ???????? ???????????? ?????? ?? ???? ??? ???????????
??????????? ???????????? ??? ????????????? ?????????????????????????????????????? ?????
??????????????????????????????????????????????????????????????????????????
 
???????????????????????
?? ????? ???? ????? ? ???????? ??????? ??? ???? ???????? ???? ???? ????????? ??? ???? ?????????
?????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
???????????? ???? ????????? ??? ????? ????? ????? ??????????? ??? ????????????? ????
???????????????????????????????????
?
?? ????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
????????????????????????????????????? ???????????????????????????????????????
???????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????
?? ??????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????
????????????????
?? ?????????????????????????????????????????
????????????????????? ???????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????
?????????
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 22 
 
 
????????????????????????????????????????????????????????????????????????????????? ???
?????????????????????????????????????? ??????????????????????????????????????? ????????
?????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? ????? ??????????????????????????????????????????????? ????????????????
?????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
???? ???????????????????? ????????? ???????? ??????????? ???????????? ??? ??????????????????
??????????? ????? ????????? ?????????? ???? ??? ???? ?????? ????? ???????? ??????????? ????
??????????????????????????????????????
 
????????????????????????????????????
???? ???????? ???? ????????? ????? ????????? ????? ??? ????????????? ????? ????? ????????????
???????????????????????????????????????????????????????????????????????????? ?????????
???????????????????????????????????????????????????????????????????????????????????? ???
?????????? ?????????? ???? ????????? ??? ???? ??????? ????? ????? ????? ???? ????????? ????????? ????
??????????????????????????????????????????????????? ???????????????????????????????????
???????????????
?????????? ????????? ?? ???????? ???? ???????? ???????????? ??????????? ??? ?????? ???????? ???
??????????? ????? ??? ?????????? ???????? ???????? ???????? ??????????? ??? ????????????? ???
???????????????????????????? ????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???? ?????????? ?? ?????? ????????????? ???????????? ??? ????????????? ?????????????? ???????????
??????? ??????? ?????????? ???? ??????? ?????? ????????????? ????????? ??????????? ???? ????? ???
????????? ????????????????? ????? ?????? ??????????? ??? ???????? ???????????? ???? ???????? ?????
????????????????????????????????????????????? ??????????????????????????????????????????
????????????????? ????????? ??????????????????????? ???????????????????????????????????????
???????? ???????????? ???????????? ???????? ??????? ???????????? ???? ???????????
????????????????? ??????? ????? ???? ????? ??? ????????????? ????????????? ????????????
????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????? ????????????
???????? ??????????? ???? ??????????? ??? ????????????????? ??????????? ?????????? ????? ?????
???????????????? ?????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
??????????? ???? ?????????? ???????? ?????????????? ???? ???????????? ????????? ???? ????????
??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 23 
 
 
????????? ??? ???? ?????? ?? ???????????? ????????? ??????????? ????? ?????? ??????????? ???
????????????? ??????????? ??????????? ???? ??? ???????? ????????????? ??????????? ??? ????
?????????? ????????? ????? ????? ???? ????? ????? ???????? ?? ????????? ??? ???????? ????????
?????????????????????? ????????????????????????????????????????? ????????? ?????????
???????????? ??????????? ??????? ????? ????? ????? ????????? ??? ???????? ???????? ???????????
?????????? ????? ?????? ??????? ??? ????? ???? ??????????? ?????????? ????????????????
????????? ?????? ????? ??????????? ????? ?????????? ???????????? ??????????? ????????? ??? ????
?? ???????????????????????????????????????????????????????????????????????????????????????? 
??????? ??? ??? ??? ?????? ????????? ????? ?????????????????????????????????????????????????
??????????? ?????????????????????????????????????????????????? ??????????????????????????????
????????? ???????? ?? ???? ???????? ???????? ??????????? ????? ?????? ??????????????? ????
???????????????????????????????????????????????????????????????????????????????????????
?????????? ??????????????????????????????????????????????????????????????????? ??????????
????? ?????????????????????????????????????? ?????????????????????????????????????????????
???????? ????? ??? ?????????? ????????????? ????????? ????????? ??? ?????? ??? ???????? ????????
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????? ??????????? ???? ???????????????? ???? ??????????????????????
?????????????????? ?????? ?????? ????????????? ??? ????????????????????????????? ???????? ?????
???????????? ????????????????????????????
??????????????????????????????????????????????????????? ????????????????????????????????
????? ???? ??????? ??? ???? ?? ????????? ?????????? ???? ????????????????? ????????? ??? ????
????????????????? ??????????????????????????? ????? ?????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????? ????????????????????????????????????????????????
????????????????????????????????????? ?????????????????
?
Summary of the introductory section 
?????????????????????????????????????????????????????????????????????????????????
???????????? ???? ??????????? ???????? ???? ?? ????????? ?????????? ??? ????????????????????
????????? ??? ????? ??????? ????????? ??? ???? ???????? ????? ?????? ????? ??? ????? ??????????
????????????????????????????????????????????????????????????????????????????????????
???? ??????????????????????????????????????????????????????????????????? ?????????????
???????? ??? ???????? ????????? ??? ? ?????? ???? ???????? ??????????? ????????? ???????? ??
??????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 24 
 
 
????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????
?????????? ????? ????????? ?????????? ???? ????? ???? ?????? ????? ???????? ??????????? ????
????????????????? ??????????? ?????????? ?????? ?????? ???? ??????????? ????? ???????
?????????? ??? ???? ???????? ???? ??????? ????? ?????????? ????? ???? ????????????? ????????
?????????? ????????????????????? ???? ?? ?? ??? ???? ???????? ???? ???????????? ???? ????? ???
??????????????????????????????????????????????????????????????????????????????????????
???????????? ??????????? ????????? ????????????? ????? ???? ????????? ????????? ????????????? ???
????????????????????????????????????????????????????????????????????????????????????????
?????? ????????????? ?? ??????????? ?????????? ???????? ??????????? ???? ?????? ???????????
????????????????? ????????? ???? ??????????? ??? ?? ???????? ?????? ????? ???? ??? ??????????
????????????????????????????????????????????????????????????????????????????????????
  
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 25 
 
 
Hypothesis 
 
??????????????????????????????????????????? ??? ???????????????????????? ????????????
????? ?????????????? ???? ???????? ??????? ?????????????? ??? ??????????? ????????
???????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????? ???????????????????????
?????????? ????????????????? ??????????? ?????????? ?????????? ???? ???????? ?????????
???????????? ???????? ??? ???? ????????????? ???????? ???? ??????????? ???? ????????? ??? ????
??????????????????? ??????????????? ???????? ??? ???? ?????? ????????????????????????????
??????????????????????
???????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? ???????????????????????????????????????? ???
?????? ???? ??????????? ??????????? ??????????? ??? ????? ???????????? ???????? ???????
????????????????????????????????????? ???????????????????????? ???????????? ????????
????????????????????? ???????????????????????????????????????????????????????????
????? ?? ????????? ????? ??? ???? ????????? ??????????? ?????? ????????? ???????????????
???????????????????????????????????? ?????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????? ???????????????????
??????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????
 
  
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 26 
 
 
General objectives 
?????????????????????????????????????????????????????????????????????????????????????????????
??? ???? ?????????????? ????????? ??? ???? ??? ???????? ???? ???? ???????????? ????????? ???
?????????????? ???? ??????????? ??? ??????????????? ???????? ???? ?????????????? ????????
???????????????????????????????? ??????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????
???????? ?????? ???? ???????????????? ??? ????????????????????????????????? ????????????
?????????????????????????????????????????????????????????????????????????????? ????????
????????????? ????????????????? ??????????? ??? ?????????? ?????? ???????? ?????????
?????????????????
 
 
Specific objectives 
?????????? ?? ?? ????????????? ????????? ???????? ????????? ???????????? ????
??????????????????????????????
???????????
?????????????????????????????????????????????????????????????? ???????????????????????????
???????????????????????????????? ????????????? ???????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
???????????? ?????????????????? ???? ??????????? ???? ??????????? ??? ???? ????????? ??? ????
? ??????????????????????????????????????????????????? ????????????????????????????????
???????????? ??????????????????????????????
?
??????????????
????? ???????????????????????????????????????????????????????????? ? ????????????
????????????????? ??? ??? ?????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
?
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 27 
 
 
???????????????
????????????????????????????????????????????????????????????????????????????? ???
????????????????? ???????????? ??????????????????????????? ????????????????????????????????
?
???????????????
????????????????????????????????????????????????????????????????????????????????
??????????????? ???????????? ???????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????
?
?????????????? ???????????? ??? ?????????????????? ????????????????????????? ?????
??????????????????????????????????????????????????????????????????????????????
??????????
???????????
?????????????????????????????????????????????????????????????????????????????????????????
???????? ???? ???? ???????????? ???????? ??????????? ????? ???? ??? ????????? ???? ????????
?????????????????????????????????????????????????????????????????????????????????????
????????????????? ????????????????????????????????????????????????????????????????
???? ?????????? ????????? ??????????? ??? ???????? ???? ?????????? ???? ???? ??????? ????
???????????? ??? ??????????????? ?????? ?????? ???????? ???? ????????????????? ???????????
???????????????????????????????????????????????????????????
?
???????????????
?????????????????????????????? ????????????????????????????????????????????????????
???????????? ?????????????? ????????????????????????????????????????????????????????
???? ?????????????? ?? ???????? ??? ?????????????? ????? ?????????? ???? ???????? ???
????????????????????????????????????????
?
??????????????
?????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????
?
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 28 
 
 
?????????????
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ??????????????????????????
? ?
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 29 
 
 
Results 
 
 
Manuscript 1:  
 
 
Importance of mitochondrial in maximal O2 transport and utilization: A 
theoretical analysis.  
 
Cano I, Mickael M, Gomez-Cabrero D, Tegnér J, Roca J, Wagner PD. 
 
?
 
 
 
Published in Respiratory Physiology & Neurobiology 
 
 
Respir Physiol Neurobiol 2013; 189: 477–483 
  
 
 
Predictive Medicine for Chronic Patients in an Integrated Care Scenario 30 
 
 
IMPORTANCE OF MITOCHONDRIAL PO2 IN MAXIMAL O2 TRANSPORT AND UTILIZATION 
 
 
I Canoa*, Mickael Mb, D. Gomez-Cabrerob, J Tegnérb, J Rocaa, PD Wagnerc 
aHospital Clinic, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Catalunya, Spain. 
bUnit of Computational Medicine, Center for Molecular Medicine, Karolinska Institute and 
Karolinska University Hospital, Stockholm, Sweden. cSchool of Medicine University of California, 
San Diego, San Diego, CA  92093-0623A.  
*Corresponding author: Isaac Cano, iscano@clinic.ub.es, IDIBAPS, C/Villarroel 170, 08036, 
Barcelona, Spain.  
 
 
ABSTRACT 
In previous computational analyses of how the O2 transport system limits V̇O max, we have 
made the approximation that mitochondrial PO2 (Pm) is sufficiently low that it can be 
neglected. We investigated the putative influence of a non-zero Pm on these calculations. To 
this end, we developed an integrative model of O2 transport and utilization by coupling previously 
used equations for mass transport to that for mitochondrial respiration. Inputs are ventilation, 
cardiac output, lung and muscle diffusing capacity, [Hb] and acid base status for the transport 
portion, and now mitochondrial P and V̇	
 for the hyperbolic mitochondrial respiration curve 
relating mitochondrial V̇O to PO2. Outputs are, V̇Omax, alveolar, arterial and venous PO2, and 
now also Pm. Simulations of healthy fit subjects exercising at sea level and altitude showed 
that depending on the effective balance between O2 transport capacity and mitochondrial 
oxidative metabolic function, Pm may vary over a wide range and, especially at elevated levels, 
contribute significantly to limiting V̇Omax.  
 
Keywords: bioenergetics, mitochondrial respiration, mitochondrial PO2, oxygen transport, 
V̇Omax. 
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1. Introduction 
At rest or during exercise, production of ATP requires both physical O2 transport from the environment 
to the mitochondria and subsequent chemical utilization of O2 by oxidative phosphorylation. Oxygen 
transport has been well described (Dejours, 1966; Gnaiger et al., 1998; Weibel et al., 1981) based on the 
O2 transport pathway, consisting of the lungs/chest wall, the heart, vascular tree and blood, and the 
tissues. These structures conduct O2 as an in-series system in which the main sequential transport steps 
are ventilation, alveolar-capillary diffusion, circulatory transport, and tissue capillary to mitochondrial 
diffusion. At each step, the mass of O2 must be conserved, and this allows a set of simple equations to 
be defined that quantifies how the transport process at each step integrates with those of the other steps 
to determine how much O2 is delivered to the mitochondria per minute (Wagner, 1993, 1996b).  
A central conclusion from such analyses is that maximal mitochondrial O2 availability is governed by 
the integrated behavior of this system rather than by any single step. Systems physiological 
investigations (Wagner, 1993, 1996b)  targeting the understanding of the limits to maximal V̇O, have 
previously been performed on the basis of an important simplifying approximation. This has been that 
the downstream mitochondrial PO (Pm) is so small in comparison to tissue capillary PO that it can 
be ignored and therefore set to zero, thus making the analyses of O2 transport much more tractable.  
However, because O2 is one of the molecules that drive oxidative phosphorylation according to the law 
of mass action, this approximation cannot be physiologically correct, or otherwise V̇O would itself be 
zero. 
Given that Pm must be larger than zero, the PO2 difference between red cells and mitochondria must 
be less than when Pm is assumed to be zero, and thus the diffusive movement of O2 between them 
must also be reduced. Therefore, if Pm is now considered as greater than zero, there is an additional 
resistance, from the process of mitochondrial respiration, to O2 movement through the entire pathway 
of O2 transport and utilization. This additional resistance must reduce maximal V̇O below that which 
would be expected if this resistance were ignored. Clearly, the degree to which V̇Omax would be 
reduced will depend on how the high mitochondrial PO2 rises above zero. This in turn will depend 
broadly on the capacity for O2 transport (how many O2 molecules can be delivered to the mitochondria 
per minute) compared to the capacity for metabolism (how many O2 molecules can be consumed by the 
mitochondria per minute).  
The importance of including consideration of oxidative phosphorylation goes beyond asking how much 
does mitochondrial respiration contribute to the overall impedance to V̇O. Because the value of Pm is 
dependent on the mitochondrial respiration curve/O2 transport interaction, hypoxia-induced biological 
changes may be affected by this interaction. 
The purpose of the present paper is therefore to expand the prior theoretical analysis of the integrated 
O2 transport pathway (Wagner, 1993, 1996a) by analyzing the consequences of allowing mitochondrial 
PO2 to be greater than zero. This requires integration of the previously described O2 transport equations 
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with an equation for mitochondrial respiration, followed by the application of mass conservation 
principles to solve this new equation system. 
 
2. Material and methods 
2.1. Principles 
Oxidative phosphorylation ensues via the following equation 1 that embodies the law of mass action: 
 
   3ADP +  3P +  NADH +  H  + 1 2⁄ O  →  3ATP + NAD  +  H0  eq. 1 
 
In this equation, Pm corresponds to O2. Clearly, this mass action equation can only move from left to 
right and produce ATP if Pm is greater than zero. 
To illustrate this effect, a graphical depiction of mitochondrial respiration is presented in Figure 1. Here, 
the solid line is the relationship between velocity of the reaction (i.e., mitochondrial V̇O), and Pm, 
similar to what has been found experimentally (Gnaiger et al., 1998; Scandurra and Gnaiger, 2010; 
Wilson et al., 1977). It shows how V̇O is a positive but non-linear function of mitochondrial PO, and 
indicates that at low Pm, V̇O is very sensitive to (and thus limited by) PO, while at higher Pm, 
V̇O becomes independent of PO, and is limited by factors other than O2.  
The hyperbolic curve through the origin displayed in Figure 1 represents mitochondrial respiration. It 
is of note that despite mitochondrial respiration kinetics is not really a Michaelis-Menten type (Johnson 
and Goody, 2011; Michaelis and Menten, 1913), experimental data (Gnaiger et al., 1998; Scandurra and 
Gnaiger, 2010) are well fitted by such a curve. As a hyperbola, it can be represented by equation 2: 
 
   V̇O = V̇	
 ·  Pm Pm +                                                                                          eq. 2 
 
Where V̇O is mitochondrial V̇O (the ordinate in Figure 1); V̇	
 is the asymptote of the curve, and 
represents the maximal rate of use of O2 when O2 is in excess; Pm is mitochondrial PO (the abscissa 
in Figure 1) and P is the PO at 50% of V̇	
. Thus, the mitochondrial respiration curve is defined by 
two parameters: V̇	
 and P. 
Also shown in Figure 1 is a straight (dashed) line of negative slope. It represents the Fick law of 
diffusion and depicts diffusive O2 transport between the tissue capillary and the mitochondria as a 
function of mitochondrial PO2 for a given tissue O2 diffusional conductance (DM) and a given tissue 
mean capillary PO2 (Pc), both at maximal exercise.  We previously utilized this representation as a 
tool for interpreting intracellular oxygenation data obtained using magnetic resonance spectroscopy 
(Richardson et al., 1999). The equation is as follows: 
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    V̇O = DM · Pc − Pm                                                                                                           eq. 3 
 
As the figure indicates, as Pm is increased, V̇O in eq (3) must fall because the PO2 difference between 
mean capillary and mitochondrial PO2 is reduced. Thus, Figure 1 shows how V̇O increases with 
mitochondrial PO2 according to oxidative phosphorylation, but decreases with mitochondrial PO2 
according to the laws of diffusion.  
The key concept in Figure 1 is that in a steady state of O2 consumption, V̇O given by both equations 2 
and 3 must be the same at the same mitochondrial PO2 (i.e., the law of mass conservation applies). This 
can occur only at the single point of intersection between the two relationships, as indicated by the solid 
circle placed there.  If, as previously approximated (Wagner, 1996b), mitochondrial PO2 were truly zero, 
V̇O would be higher, as indicated by the open circle at the left end of the dashed straight line in Figure 
1. For a given O2 transport system defined by the conductances for O2 allowed by ventilation, alveolar-
capillary diffusion, circulation, and capillary to mitochondrial diffusion, the values of mitochondrial 
V̇	
 and P (equation 2) will thereby influence maximal rate of O2 utilization, V̇Omax. In the 
remainder of this paper, it will be important to distinguish between V̇	
 (the asymptote to the 
mitochondrial respiration curve) and V̇Omax (actual maximal rate of O2 utilization, solid circle in 
Figure 1) to avoid confusion. In general, V̇	
 can exceed V̇Omax, but V̇Omax cannot exceed V̇	
. 
 
2.2. Modeling the O2 transport/utilization system 
The present study augments our prior approach (Wagner, 1993, 1996b) by adding equation (2) to the 
equation system used previously. Figure 2 recapitulates the O2 transport pathway, and the associated 
four mass conservation equations governing O2 transport at each step. It adds Equation (2), describing 
O2 utilization as a function of Pm. The important point is that in this way, the system has expanded 
from four equations with four unknowns into a system of five equations and five unknowns.  
Briefly, using specified input values for O2 transport step parameters (i.e., values of inspired O2 fraction 
(FI), ventilation (V̇I, inspired; V̇A, expired), lung diffusing capacity (DL), cardiac output (Q̇), [Hb], 
acid base status, tissue (muscle) diffusing capacity (DM), and mitochondrial respiration curve 
parameters (V̇	
 and P)), five mass conservation equations are written for O2 (see Figure 2). They 
describe (a) ventilatory transport; (b) alveolar-capillary diffusion; (c) circulatory transport; (d) muscle 
capillary-mitochondrial diffusion; and (e) mitochondrial respiration. There are five unknowns in these 
equations: Alveolar PO (PA), arterial PO (Pa), venous PO (Pv), mitochondrial PO (Pm) 
and V̇O itself. In Figure 2, equations (b) and (d) are differential equations describing the process of 
diffusion across the lung blood: gas barrier and across the tissue capillary wall respectively. They 
specifically describe the time rate of change of O2 concentration, [O2], along the respective capillary as 
a function of the diffusing capacity, blood flow, red cell capillary transit time (T (lungs); T (tissues)) 
and the instantaneous difference between upstream and downstream PO2 values (alveolar and pulmonary 
 Predictive Medicine for Chronic Patients in an Integrated Care Scenario 34 
 
 
capillary in (b); capillary and mitochondrial in (d)). The two equations are each expressions of the Fick 
law of diffusion. 
The additional inputs of mitochondrial V̇	
 and P, and the additional coding for the fifth equation 
were added to the prior model, and the same (numerical) method of solution employed before (Wagner, 
1996b) was used to find the solutions for any set of input variables, defined as the unique values of the 
five unknowns listed above that simultaneously satisfy all five equations for the given input data 
defining O2 transport and utilization. 
 
2.3. Input data for simulations 
The input data defining the O2 pathway parameters used in this analysis were essentially identical to 
those used previously (Wagner, 1996b), and come from Operation Everest II (Sutton et al., 1988). They 
reflect maximal exercise by normal subjects at sea level, at a chamber “altitude” of 4,573 m 
(approximately 15,000 ft.) and at the chamber altitude of the Everest summit, 8,848 m (approximately 
29,000 ft.). They are reproduced in Table 1. It is clear that data do not exist for the two new key 
variables: mitochondrial V̇	
 and P. Therefore, for each of the three data sets we computed solutions 
to the equation system over a systematic range of five mitochondrial V̇	
 (1000, 2000, 3000, 4000, 
and 5000 ml/min) and four mitochondrial P values (0.1, 0.3, 0.5 and 1.0 mm Hg), resulting in 20 
combinations of the two, and thus 20 mitochondrial respiration curves. The values of V̇	
 were chosen 
to encompass the range of V̇Omax from the very sedentary to the elite athlete. Values of P on the 
other hand were based on physiological studies inscribing the mitochondrial respiration curve from 
samples of normal muscle (Gnaiger et al., 1998; Scandurra and Gnaiger, 2010).  
A typical example from one of these papers is reproduced with permission in Figure 3, where the 
hyperbolic character of the curve and its P can both be seen by the fitted curve. In this and other similar 
published cases (Gnaiger et al., 1998; Scandurra and Gnaiger, 2010), P is close to 0.3 mm Hg. This 
accounts for our choice of P values - from a third of this typical value to about threefold greater. 
However it should be stressed that the modeling can be based on any combination of P and V̇	
, and 
need not be limited to the choice of specific parameters appearing here. 
 
2.4. Analysis 
Across the matrix of V̇	
 and P values, we posed two questions: First we asked how much would 
Pm have to rise above zero to satisfy mass conservation and drive mitochondrial respiration for the 
given set of physiological O2 transport variables, V̇	
 and P - and as a result, how much would that 
cause V̇O to be reduced (compared to assuming Pm = 0) as per Figure 1 (comparing the open and 
closed circles). This question allows a quantitative description of the theoretical consequences for 
V̇Omax of any combination of mitochondrial V̇	
 and P. While this is a very useful question to 
answer, in reality V̇Omax is a directly measured variable. Therefore, asking how much would it be 
 Predictive Medicine for Chronic Patients in an Integrated Care Scenario 35 
 
 
reduced by any pair of V̇	
 and P values is hypothetical.  On the other hand, muscle diffusing 
capacity, DM, is a variable calculated on the assumption that mitochondrial PO2 can be neglected and 
set to zero – the very approximation that the present study is addressing.  
Thus, another way to interrogate the model system can be proposed, leading to a second question: It 
recognizes that the muscle O2 diffusion step was previously modeled, and muscle diffusing capacity 
estimated, on the basis of Pm = 0. However, if Pm is greater than zero, the capillary to 
mitochondrial O2 diffusion gradient would be reduced, and this would necessitate, by the Fick law of 
diffusion, a higher value of DM to accomplish a given, measured V̇Omax (compared to the value 
calculated assuming Pm = 0). 
Therefore, for each of the combinations of V̇	
 and P, we asked how much would muscle diffusing 
capacity have to increase to maintain V̇O constant at the measured value as a result of Pmbeing 
greater than zero. 
 
3. Results 
3.1. Effects of mitochondrial respiration on  and maximal ̇ 
Figure 4 shows how the different combinations of mitochondrial V̇	
 and P affect V̇Omax. The 
upper panel covers the mitochondrial PO2 (Pm) range from zero to 20 mm Hg; the lower panel shows 
the same data, but expands the abscissa to better reflect the lower Pm range between zero and 5 mm 
Hg. In both panels, each solid curved line emanating from the origin represents one of the twenty 
mitochondrial respiration curves (as in Figure 3) for a particular V̇	
 and P combination. Solid 
circles reflect sea level conditions; solid squares represent moderate altitude and solid triangles are for 
the equivalent of the Everest summit. It turns out that at each altitude, an approximately straight line can 
be drawn through the resulting V̇Omax/Pm solution points for each mitochondrial respiration curve. 
These are the dashed lines in the figure. 
The values of V̇Omax at each altitude at the point where Pmequals zero (open symbols at zero Pm) 
are the same as those described in (Wagner, 1996b) where Pm was taken to be zero. The figure shows 
how relaxing that approximation affects V̇Omax for each combination of mitochondrial V̇	
 and P. 
At sea level (solid circles), results show that allowing for a non-zero Pm has a small but significant 
impact on V̇Omax. For example, V̇Omax at Pm = 0 mm Hg (open circle) would be 3,827 ml/min, 
but if V̇	
 were 4,000 ml/min and P50 1.0 mm Hg, V̇Omax would be significantly less, by 9%, and 
would be 3,477 ml/min. Moreover, this would require a mitochondrial PO2 of 6.7 mm Hg to drive 
oxidative phosphorylation, as the figure shows. In general, for the fixed set of O2 transport parameters 
used (see Table 1), the lower the V̇	
 and the higher the P50, the greater is the reduction in V̇O, and 
the higher is the Pm required to drive ATP generation. The range of possible values of mitochondrial 
PO2 is considerable, from a fraction of a mm Hg to more than 10 mm Hg, depending on V̇	
 and P50. 
 Predictive Medicine for Chronic Patients in an Integrated Care Scenario 36 
 
 
The same outcome is seen at each altitude, but with V̇O lower at any Pm as PIis reduced. The 
reduction in V̇O per unit change in Pm is somewhat less at altitude than at sea level, but if examined 
as a percent of V̇O at Pm = 0  at each altitude, the effects of allowing for mitochondrial respiration 
on maximal V̇O are relatively similar across altitudes.  
In summary, the higher the mitochondrial V̇	
 and the lower the P50, the more O2 can be metabolized 
for a given upstream (heart, lungs, blood, muscle) transport system. Mitochondrial PO at V̇Omax can 
be neglected when considering O2 transport only when mitochondrial P50 is low and mitochondrial V̇	
 
is high. When V̇	
 is low and/or P50 is high, the mitochondrial PO2 required to drive oxidative 
phosphorylation may reach double digit values, and the impact on V̇Omax  can be considerable. 
 
3.2. Maintenance of maximal ̇ in the face of non-zero  
The preceding subsection showed how V̇Omax would have to decrease as a function of mitochondrial 
V̇	
 and P50 with constant values for all O2 transport conductances. In this subsection we investigate 
how much higher the muscle O2 diffusing capacity would have to be to maintain V̇Omax constant over 
the same range of V̇	
 and P50 values as Pm increases above zero.    
The results are shown in Figure 5, which displays the simulation outcomes across the entire matrix of 
V̇	
 and P50 values, using V̇	
 on the abscissa and isopleths for each P50. Results are shown for each 
altitude as indicated by the different symbols. The top panel shows mitochondrial PO2 for every 
combination of V̇	
 and P50 examined, and the bottom panel the corresponding values of muscle 
diffusing capacity (DM), that would have to exist to maintain V̇Omax at measured levels (indicated at 
each altitude by the vertical dashed lines). Comparing panels shows that when Pm is high (thus 
reducing the PO2 gradient between capillaries and mitochondria), DM must also be high to maintain 
diffusive O2 transport.  
Also, when mitochondrial V̇	
 substantially exceeds measured V̇Omax (at each altitude), 
Pm remains low, and therefore DM does not need to be substantially increased to maintain O2 flux. 
However, the closer mitochondrial V̇	
 is to measured V̇Omax, the higher Pm must be (see Figure 
4), and therefore, DM is also required to be elevated to maintain O2 transport.  When V̇	
 and actual 
V̇Omax are very close, the required DM may be as much as four times the value needed when Pm is 
(close to) zero, and the associated Pm would reach double digit values. 
 
4. Discussion 
4.1. Summary of major findings 
In this simulation of normal fit subjects exercising maximally at sea level and at altitude, incorporating 
mitochondrial respiration kinetics into a systems analysis of O2 transport and utilization reveals that 
mitochondrial respiration generally poses only a small additional resistance to the system (over that of 
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the transport pathway alone). Nevertheless, this must reduce V̇Omax below that computed ignoring 
this contribution (Figure 4). The associated mitochondrial PO2 would also be low, generally < 1 mm 
Hg. This finding is based on the evident low muscle mitochondrial P50 of 0.30 mm Hg (Gnaiger et al., 
1998; Scandurra and Gnaiger, 2010). If however mitochondrial V̇	
 was low in relation to O2 transport 
capacity, or if mitochondrial P50 were higher than reported values (Gnaiger et al., 1998; Scandurra and 
Gnaiger, 2010), V̇Omax would fall more. Mitochondrial PO2 would then rise more, and could reach 
double digit values. In order to maintain V̇Omax in the face of reduced V̇	
 or increased P50, muscle 
diffusing capacity (DM) would need to be higher than when Pm is assumed to be zero. Under most 
conditions examined in the present study, the necessary increase in DM would be minimal, and only 
when Pm is considerably elevated would DM have to be comparably increased to overcome the loss 
of the PO2 gradient driving diffusion between capillaries and mitochondria. This would happen when 
mitochondrial V̇	
 and actual V̇Omax are closely similar (Figure 5). 
 
4.2. Unifying principles  
The main principle demonstrated in the present study is that the final step in the O2 pathway – 
mitochondrial respiration – may contribute a non-negligible resistance to O2 movement through the 
system from the air to its conversion to CO2, resulting in a lower V̇Omax compared to a system where 
metabolism imposed no resistance to overall O2 flow. The higher the mitochondrial PO2 required to 
drive oxidative phosphorylation, the greater would be the relative resistance and thus the more effect 
there will be on reduction in V̇Omax. When mitochondrial P50 is about 0.30 mm Hg as reported by 
Gnaiger (Gnaiger et al., 1998; Scandurra and Gnaiger, 2010) the effects are generally minor. 
The simulations at the three inspired PO2 values shown here demonstrate that it is the relative capacities 
(rather than individual absolute values) of the physiological transport system and the mitochondrial 
respiratory chain that effectively determine both the mitochondrial PO2 and the associated effect on 
V̇Omax, and that both variables, but especially mitochondrial PO2, may vary over a wide range 
depending on mitochondrial respiratory function. 
An additional important principle is shown in Figure 6: Even when O2 transport capacity (i.e., potential 
for O2 delivery) is considerably greater than mitochondrial respiratory capacity (i.e., potential for O2 
utilization), as illustrated in concept in the top panel, a change in the former will change overall V̇O.  
The converse is also true – that when mitochondrial respiratory capacity exceeds O2 transport capacity, 
(lower panel), a change in the former will have an effect on V̇O. It is thus not correct to think that when 
one component is greater than the other, only the lesser of the two determines overall V̇Omax.  This 
conclusion is much the same as described for individual components of the physiological transport 
pathway of the lungs and chest wall, the heart, blood and circulation, and the muscles, where we 
previously showed (Wagner, 1996a, b) that all components affect V̇Omax, not just the step with the 
least transport capacity. 
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4.3. Effects of mitochondrial respiration kinetics on both ̇ and  may be small or large 
For the examples shown – fit normal subjects – the effects of considering mitochondrial respiration are 
generally less on V̇O than on the associated Pm (Figure 4).  Examining the sea level results for the 
example of V̇	
 = 4,000 ml/min and P50 increasing from 0.1 to 1.0 mm Hg, V̇Omax would fall by 9% 
while Pm would increase by an order of magnitude, from less than 1 mm Hg to more than 6 mm Hg. 
Just how much variation there is in mitochondrial P50 in the normal population is unknown, let alone 
whether this may change systematically with training, or in chronic diseases such as chronic obstructive 
pulmonary disease (COPD) or chronic heart failure. The calculations presented herein however point 
out that the quantitative nature of the mitochondrial respiration curve may be a critical determinant of 
the values of mitochondrial PO2 and V̇Omax, over and above any influence of upstream O2 transport. 
Even if the effects on V̇Omax are numerically small, they would likely be important in the competitive 
endurance athlete where very small differences may separate success from failure. But possibly even 
more significant might be the potentially large variation in mitochondrial PO2 depending on P50 and 
V̇	
 due to known hypoxia-induced biological effects  (Semenza, 2011).  Thus, hypoxia-induced gene 
expression or reactive O2 species generation may vary according to mitochondrial PO2.   
 
4.4. Potential for estimating mitochondrial P50 based on the current modeling approach 
The analysis presented here suggests a possible method for estimating the characteristics of the 
mitochondrial respiration curve in vivo. Currently, mitochondrial V̇	
 and P50 are measured in vitro in 
respirometers where mitochondria are exposed to different levels of O2 and V̇O measured (as in Figure 
3), (Gnaiger et al., 1998; Scandurra and Gnaiger, 2010; Wilson et al., 1977). To obtain this information 
in humans would therefore necessitate a muscle biopsy, and even if that were done, the result would be 
subject to the usual sampling constraints as for any other measure of muscle structure or function 
determined from a single biopsy.  
The fitting of a hyperbolic function to paired measured values of V̇Omax and mitochondrial PO2 has 
the potential for estimating P50 and V̇	
 in vivo, and this is illustrated in Figure 7. The intervention to 
garner several points on the curve would come from acutely varying FI and measuring V̇O and 
mitochondrial PO2 during maximal exercise at each FI, as indicated by the theoretical example of the 
two solid circles in the upper panel of Figure 7. These two points reflect a mitochondrial respiration 
curve with P50 of 0.30 mm Hg and V̇	
 of 4,000 ml/min. If such data were to span both the steep and 
flat parts of the respiration curve, as shown in the figure, identifying the V̇	
 and P50 of a hyperbola 
that resulted in a least squares best fit to the data points would be possible, as shown in the lower panel 
of Figure 7. Here, over a range of trial values of both V̇	
 and P50, the root mean square (RMS) residual 
V̇O between the data and the hyperbola corresponding to each trial combination of P50 (and the 
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V̇	
 providing the lowest RMS for that P50) is shown. In this error-free theoretical case, one could quite 
accurately estimate V̇	
 (4,000 ml/min) and P50 (0.3 mm Hg) from the values at the nadir of the 
relationship in the figure. However, if measured data happened to lie on only the flat or only on the steep 
parts of the curve, ability to estimate V̇	
 and/or P50 would be considerably reduced.  
While whole body or large muscle mass V̇O can be measured relatively easily, the experimental 
challenge would be to measure mitochondrial PO2 (during exercise) (Mik, 2013). The closest approach 
to date in intact subjects has used MRS-based determination of myoglobin O2 saturation (Jue et al., 
1994; Richardson et al., 1995), where the signal comes from a relatively large muscle region.  This 
approach gives intracellular PO2 estimates of 3-4 mm Hg during exercise (Richardson et al., 1995), but 
this is the PO2 associated with myoglobin, inferred from the finding of about 50% myoglobin saturation 
during peak exercise combined with accepted values of myoglobin P50 of about 3 mm Hg (Rossi-Fanelli 
and Antonini, 1958). This PO2 is an order of magnitude greater than that projected at the mitochondria 
based on the preceding discussion. In the end, a method would have to be developed for direct 
measurement of mitochondrial PO2. Whether a candidate signaling atom or molecule can be found for 
an MRS-based approach is currently unknown.  
 
5. Conclusions 
Considering the hindrance to overall O2 flux caused by mitochondrial respiration using an established 
model of O2 transport to the mitochondria revealed that in normal subjects exercising maximally, the 
step of oxidative phosphorylation, with its requirement for a mitochondrial PO2 > 0, likely plays only a 
small role in total O2 flux resistance. However, we identified conditions in which mitochondrial PO2 can 
rise to double digit values. This occurs particularly when the mitochondrial respiration curve has either 
a low V̇	
 (relative to O2 transport), or a high P50, and under such conditions, mitochondrial function 
may significantly impair O2 flux.  
 
ACKNOWLEDGEMENT 
 
 
We would like to acknowledge the contributions made by the Synergy-COPD consortium and NIH 
P01 HL091830.   
 Predictive Medicine for Chronic Patients in an Integrated Care Scenario 40 
 
 
REFERENCES 
 
Dejours P, and Kayser C. Respiration. Oxford University Press, 1966.  
Gnaiger, E., Lassnig, B., Kuznetsov, A., Rieger, G., Margreiter, R., 1998. Mitochondrial oxygen 
affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J Exp Biol 201, 
1129-1139. 
Johnson, K.A., Goody, R.S., 2011. The Original Michaelis Constant: Translation of the 1913 Michaelis–
Menten Paper. Biochemistry 50, 8264-8269. 
Jue, T., Kreutzer, U., Chung, Y., 1994. 1H NMR approach to observe tissue oxygenation with the signals 
of myoglobin. Adv Exp Med Biol 361, 111-118. 
Michaelis, L., Menten, M.L., 1913. Die kinetik der invertinwirkung. Biochem. Z 49, 352. 
Mik, E.G., 2013. Measuring Mitochondrial Oxygen Tension: From Basic Principles to Application in 
Humans. Anesthesia and analgesia. 
Richardson, R.S., Leigh, J.S., Wagner, P.D., Noyszewski, E.A., 1999. Cellular PO2 as a determinant of 
maximal mitochondrial O2 consumption in trained human skeletal muscle. J Appl Physiol 87, 
325-331. 
Richardson, R.S., Noyszewski, E.A., Kendrick, K.F., Leigh, J.S., Wagner, P.D., 1995. Myoglobin O2 
desaturation during exercise. Evidence of limited O2 transport. J Clin Invest 96, 1916-1926. 
Rossi-Fanelli, A., Antonini, E., 1958. Studies on the oxygen and carbon monoxide equilibria of human 
myoglobin. Arch Biochem Biophys 77, 478-492. 
Scandurra, F.M., Gnaiger, E., 2010. Cell respiration under hypoxia: facts and artefacts in mitochondrial 
oxygen kinetics. Adv Exp Med Biol 662, 7-25. 
Semenza, G.L., 2011. Oxygen Sensing, Homeostasis, and Disease. New England Journal of Medicine 
365, 537-547. 
Sutton, J.R., Reeves, J.T., Wagner, P.D., Groves, B.M., Cymerman, A., Malconian, M.K., Rock, P.B., 
Young, P.M., Walter, S.D., Houston, C.S., 1988. Operation Everest II: oxygen transport during 
exercise at extreme simulated altitude. J Appl Physiol 64, 1309-1321. 
Wagner, P.D., 1993. Algebraic analysis of the determinants of VO2max. Respiration physiology 93, 
221-237. 
Wagner, P.D., 1996a. Determinants of maximal oxygen transport and utilization. Annu Rev Physiol 58, 
21-50. 
Wagner, P.D., 1996b. A theoretical analysis of factors determining VO2 MAX at sea level and altitude. 
Respiration physiology 106, 329-343. 
Weibel, E.R., Taylor, C.R., Gehr, P., Hoppeler, H., Mathieu, O., Maloiy, G.M., 1981. Design of the 
mammalian respiratory system. IX. Functional and structural limits for oxygen flow. Respiration 
physiology 44, 151-164. 
Wilson, D.F., Erecinska, M., Drown, C., Silver, I.A., 1977. Effect of oxygen tension on cellular 
energetics. American Journal of Physiology - Cell Physiology 233, C135-C140. 
 
 
 
FIGURES
Figure 1: Graphical analysis of diffusive transport of O2 from muscle capillary to the 
mitochondria (dashed line) and subsequent utilization of O2 through oxidative phosphorylation 
(solid line). See text for details. 
 
 
 
 
Figure 2: Schematic representation of the oxygen transport and utilization system considered in 
this study and the five associated mass conservation equations governing O2 transport (equations 
a-d) and utilization (equation e). 
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Figure 3: Graphical depiction of the hyperbolic equation for oxidative phosphorylation fitted to 
the data of Scandurra & Gnaiger (Scandurra and Gnaiger, 2010). p16. fig 3B). 
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Figure 4: Effects of considering mitochondrial respiration on maximal V̇O and mitochondrial 
PO2. For each V̇	
 value, the four hyperbolic curves represent P50 values of 0.1, 0.3, 0.5 and 1.0 
mm Hg, left to right. See text for details. 
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Figure 5: Mitochondrial PO2 (upper panel) and muscle O2 diffusing capacity (lower panel) 
required to maintain V̇O constant at the measured value across the domain of V̇	
 and P 
values at each altitude studied (see text for details). 
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Figure 6: Graphical depiction of the concept that even when the capacity for O2 delivery exceeds 
O2 utilization (upper panel) a change in O2 delivery will change actual V̇O. Conversely, when 
the capacity for O2 utilization exceeds O2 delivery (lower panel) a change in O2 utilization 
(increase in P50 in this example) will change actual V̇O. Open circles: maximal O2 delivery to 
mitochondria if Pm  was zero. Closed circles: actual V̇O. Solid and dashed lines: as in Figure 
1. 
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Figure 7: Estimation of mitochondrial P50. Upper panel:  least squares best fit (solid lines) to data 
(solid circles) for five trial P50 values. Lower panel: closeness of fit to data reflected by the Root 
Mean Square error, showing that a P50 of 0.30 mm Hg provides the best estimate. 
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TABLE 1 
 
 Normal subjects at… 
Parameter Sea 
Level 15,000 ft. 
Everest 
summit 
Barometric pressure (), Torr 760 464 253 
Fractional Inspired Oxygen () 0.2093 0.2093 0.2093 
Alveolar ventilation (!̇), BTPS, L·min-1 112 125 165 
Blood flow ("̇), L·min-1 23 21 16 
Hemoglobin concentration ([#$]),  g·dl-1 14.5 15.5 18.0 
Body temperature (%), °C 38 38 37 
O2 dissociation curve &'( , Torr 26.8 26.8 26.8 
Total Lung O2 diffusing capacity ()*), ml·min-1·Torr-1 51 80 100 
Total muscle O2 diffusing capacity (),), ml·min-1·Torr-1 102 88 62 
Maximum O2 uptake (!̇-./4),  L·min-1 3.82 2.81 1.46 
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Key points summary 
 We expanded a prior model of whole-body O2 transport and utilization based on diffusive 
O2 exchange in the lungs and tissues to additionally allow for both lung 
ventilation/perfusion and tissue metabolism/perfusion heterogeneities, in order to 
estimate V̇ and mitochondrial P (P67 ) during maximal exercise. 
 Simulations were performed using data from a) healthy fit subjects exercising at sea level 
and at altitudes up to the equivalent of Mount Everest and b) patients with mild and severe 
chronic obstructive pulmonary disease (COPD) exercising at sea level. 
 A given degree of heterogeneity in the skeletal muscle reduces overall O2 transfer more 
than does lung heterogeneity, but actually observed heterogeneity in lung is greater than 
in muscle, so that lung heterogeneity has a greater impact on overall O2 transport. Muscle 
heterogeneity increases the range of skeletal muscle P67 values, and in regions with a 
low ratio of metabolic capacity to blood flow, P67 can exceed that of mixed tissue venous 
blood.  
 The combined effects of lung and peripheral heterogeneities on the resistance to O2 flow 
in health decreases with altitude. 
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Abstract 
Previous models of O2 transport and utilization in health considered diffusive exchange of O2 in 
lung and muscle, but, reasonably, neglected functional heterogeneities in these tissues. However, 
in disease, disregarding such heterogeneities would not be justified. Here, pulmonary 
ventilation/perfusion and skeletal muscle metabolism/perfusion mismatching were added to a 
prior model of only diffusive exchange. Previously ignored O2 exchange in non-exercising tissues 
was also included. We simulated maximal exercise in a) healthy subjects at sea level and altitude, 
and b) COPD patients at sea level, to assess the separate and combined effects of pulmonary and 
peripheral functional heterogeneities on overall muscle O2 uptake (V̇) and on mitochondrial P 
(P67 ). In healthy subjects at maximal exercise, the combined effects of pulmonary and peripheral 
heterogeneities reduced arterial P (P87 ) at sea level by 32 mm Hg, but muscle V̇ by only 122 
ml/min (-3.5%). At the altitude of Mt Everest, lung and tissue heterogeneity together reduced 
P87 by less than 1 mm Hg and V̇ by 32 ml/min (-2.4%). Skeletal muscle heterogeneity led to a 
wide range of P67 among muscle regions, and in regions with a low ratio of metabolic capacity 
to blood flow, P67 exceeded P of mixed muscle venous blood. For patients with severe COPD, 
peak V̇ was insensitive to substantial changes in the mitochondrial characteristics for O2 
consumption or the extent of muscle heterogeneity. This integrative computational model of O2 
transport and utilization offers the potential for estimating profiles of P67 both in health and in 
diseases such as COPD if the extent of pulmonary and peripheral heterogeneity is known. 
 
Key words: Altitude, COPD; Exercise; Health, Gas exchange; Lung ventilation-perfusion 
mismatching; Maximal O2 uptake; Skeletal muscle perfusion-metabolism mismatching 
 
Abbreviations V̇max, maximum oxygen delivery-uptake; COPD, chronic obstructive 
pulmonary disease; P67 , mitochondrial P, V̇	
 mitochondrial maximal capacity for O2 
consumption. 
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1. Introduction 
Current modeling of the O2 pathway (Wagner, 1993, 1996; Cano et al., 2013) is based on the 
concept that it is the functional integration amongst all individual components of the oxygen  
transport and utilization system (i.e. lungs and chest wall, heart, blood and circulation, and 
tissue mitochondria) which determines maximal overall O2 uptake (V̇max). In these models, 
important simplifying assumptions were made. In particular, O2 exchange within the lungs 
was simplified by ignoring ventilation/perfusion (V̇	/Q̇) inequality, and exchange focused 
only on alveolar-capillary diffusion. This was felt to be reasonable as the minimal 
V̇	/Q̇ inequality found in health (Wagner et al., 1974) is normally of minor importance to O2 
exchange, while allowing for such inequality greatly increased model complexity. However, 
this would be an unacceptable simplification in cardiopulmonary diseases where 
V̇	/Q̇ inequality can be substantial. Similarly, within the muscles, potential heterogeneity of 
local metabolic capacity and demand (V̇) in relation to blood flow distribution (Q̇) was not 
considered, and while diffusive movement of O2 from the muscle microcirculation to the 
mitochondria was modeled, the muscles were considered to be functionally homogeneous, 
i.e., with blood flow perfectly matched to O2 demand throughout. Much less information 
exists about normal V̇/Q̇ heterogeneity in muscle (Richardson et al., 2001), but using NIRS, 
preliminary unpublished data in normal subjects (Vogiatzis et al, J. Applied Physiol, under 
review) suggest that V̇/Q̇ matching is much tighter than is V̇	/Q̇ matching. Additional 
unpublished data (Louvaris et al, in preparation) from patients with moderate chronic 
obstructive pulmonary disease suggest that V̇/Q̇ heterogeneity in muscle is not greater than 
in health. Thus, V̇/Q̇ dispersion in muscle appears to be only about ¼ of V̇	/Q̇ dispersion in 
normal lung.  
Another simplifying assumption was that all of the cardiac output flowed to the exercising 
muscles, which is clearly untrue. This is not of great quantitative importance to muscle O2 
transport in health because of the ability to increase cardiac output to over 20 L/min, rendering 
the fraction of cardiac output perfusing non-exercising tissue small. However, such an 
assumption would pose a substantial limitation if the models were applied to patients with 
chronic cardiorespiratory disease where peak exercise may elicit less than a doubling of the 
resting cardiac output and resting V̇. 
The purpose of the study reported in the current paper was therefore to first expand the prior 
O2 transport pathway model (Wagner, 1993, 1996; Cano et al., 2013) by allowing for a) 
V̇	/Q̇ heterogeneity in the lung, b) V̇/Q̇ heterogeneity in the muscle, and c) perfusion and 
metabolism in non-exercising tissues, and then to analyze the impact of possible 
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heterogeneity in lungs and in peripheral exercising tissues, separately and combined, on 
overall O2 transport and utilization at maximum exercise, both in health and in disease. In 
health, we simulated exercise not just at sea level but at altitudes up to the summit of Mt. 
Everest using as input data variables obtained in Operation Everest II (Sutton et al., 1988). In 
disease, we chose COPD as the example of pulmonary gas exchange heterogeneity because 
of availability of O2 transport data (Blanco et al., 2010), and because of general interest in 
muscle function in this disease. 
We then posed four questions: a) in health, what are the potential effects of lung and muscle 
heterogeneity (each modeled over a wide range) on oxygen flux and partial pressures at all 
steps in the O2 pathway at sea level; b) what is the impact of  typical normal levels of 
heterogeneity on these variables when O2 availability is reduced by exposure to high altitude; 
c) how substantial variations of the three least well established determinants of O2 flux and 
partial pressures in the transport/utilization pathway (V̇	
 and P50 of the mitochondrial 
respiration curve and the extent of muscle heterogeneity) would affect both V̇ and 
mitochondrial P estimates; and d) what is the effect of (measured) lung and possible muscle 
heterogeneity on overall oxygen uptake and mitochondrial P in mild and severe COPD, 
where O2 transport is less than normal.     
    
2. Methods 
2.1. The prior O2 transport and utilization model 
In the absence of heterogeneity in lungs or tissues, and ignoring metabolism and blood flow 
to non-exercising tissues, the system describing maximal O2 transport and utilization 
(Wagner, 1993, 1996; Cano et al., 2013) was composed of five mass conservation equations 
as shown in Figure 1, which is reproduced from (Cano et al., 2013) for the convenience of 
the reader. These equations represent: 1) O2 transport by ventilation from the atmosphere to 
alveolar gas (Eq. (a) in Figure 1); 2) O2 diffusion from the alveolar gas to the lung capillaries 
(Eq. (b) in Figure 1); 3) O2 transport through the systemic circulation (Eq. (c) in Figure 1); 
4) O2 diffusion from systemic capillary blood to the muscle mitochondria (Eq. (d) in Figure 
1); and 5) mitochondrial O2 utilization (Eq. (e) in Figure 1).  
The inputs to these equations are, at maximal exercise: inspired O2 fraction (FI), ventilation 
(V̇I, inspired; V̇A, expired), lung diffusing capacity (DL), cardiac output (Q̇), [Hb], acid base 
status, tissue (muscle) diffusing capacity (DM) and the characteristics of mitochondrial 
respiration (modeled as a hyperbolic curve with its two parameters, V̇	
 and P, as defined 
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below). The five outputs, or unknowns, in these equations are the maximal rate of O2 uptake 
(V̇max) and alveolar, systemic arterial, venous and mitochondrial PO2  values.  
While the focus is clearly on O2 transport, CO2 cannot be ignored in such a model because of 
the effects of CO2 on the O2Hb dissociation curve. Thus, the same processes and equations 
are used for CO2 (except for mitochondrial respiration, where, because the mitochondrial 
respiration curve for O2 consumption does not apply to CO2; CO2 production is related to 
V̇ through a stipulated value of the respiratory quotient) and the solutions for both gases 
sought simultaneously. 
2.2. Modeling lung ventilation-perfusion inequality 
To expand the model and allow for ventilation/perfusion (V̇	/Q̇) inequality, ventilation and 
perfusion within the lung were distributed amongst a set of virtual lung compartments, each 
defined by its own ratio of ventilation (V̇	) to blood flow (Q̇), with the compartments 
connected in parallel. This is exactly the same approach as first advanced by West in 1969 
(West, 1969). Then, the computation for diffusive alveolar-capillary exchange, previously 
applied to just a single lung compartment representing the homogeneous lung, is now applied 
to all compartments in turn. The entering mixed venous blood is the same for all 
compartments, and the task is to compute the P and P: values expected at the end of the 
capillary in each compartment of different V̇	/Q̇ ratio. This is done with a forward numerical 
integration procedure (Wagner et al., 1974), also used in (Cano et al., 2013), and the outcome 
for each compartment depends on the compartmental DL/Q̇ and V̇	/Q̇ ratios, the inspired gas 
and mixed venous blood O2 and CO2 composition, and the shape and position of the respective 
binding curves in blood. This approach is in fact the same as developed by Hammond and 
Hempleman (Hammond & Hempleman, 1987), and which is also contained within the 
multiple inert gas elimination technique (Wagner, 2008). Once all compartments have been 
subjected to this numerical integration, O2 and CO2 concentrations in their effluent blood are 
averaged in a perfusion-weighted manner to compute the O2 and CO2 profile of the systemic 
arterial blood that will reach both the exercising muscles and non-exercising tissues and 
organs. 
In the present application, two means of data entry are possible for specifying the features of 
the V̇	/Q̇ distribution, allowing flexibility: Individual compartmental values for ventilation 
and blood flow can be used, or the compartments can be calculated based on a 
V̇	/Q̇ distribution containing one or more modes, using for each mode its first three moments 
(mean, dispersion and skewness) as originally programmed by West (West, 1969). Both types 
of inputs end up providing a multi-compartmental V̇	/Q̇ distribution (indicated in Figure 1). 
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For simplicity, when computing the lung compartments based on a V̇	/Q̇ distribution, the lung 
diffusing capacity (DL) was always distributed in proportion to compartmental blood flow, 
so that compartmental DL/Q̇ remains constant throughout the lung. This decision does not 
eliminate the opportunity to introduce actual data on DL/Q̇ distribution when available. 
In summary, to allow for V̇	/Q̇ heterogeneity, the single homogeneous lung “compartment” 
in the prior model has been replaced by a multi-compartment model built from the algorithms 
of West (West, 1969) as modified by Hammond and Hempleman (Hammond & Hempleman, 
1987) and which allows for both V̇	/Q̇ inequality and diffusive exchange. Just as in the prior 
model, necessary inputs remain the composition of inspired gas and mixed venous blood, and 
the output remains the composition of systemic arterial blood destined for the muscles and 
other tissues.     
2.3. Modeling peripheral heterogeneity 
Similarly to lung ventilation/perfusion mismatch, tissue heterogeneities are considered as 
(regional) variability in a functional ratio. However, instead of V̇	/Q̇ being that ratio as in the 
lung, it is the ratio of mitochondrial metabolic capacity (V̇	
) to blood flow (Q̇) that is 
important in the muscles. Here, V̇	
 is the local mitochondrial maximal metabolic capacity 
to use O2, and is the very same parameter as V̇	
 in equation 5, Figure 1. The ratio V̇	
/Q̇ 
in essence expresses the balance between O2 supply and O2 demand, reflected by Q̇ and 
V̇	
 respectively. In the prior model, the muscle was considered homogeneous in terms of 
V̇	
/Q̇ ratios, but now the muscle is considered as a parallel collection of muscle “units” 
each with its own ratio of V̇	
/Q̇. Exactly as with the lung, the V̇	
/Q̇ distribution can be 
specified either as a set of individual compartmental values for Q̇ and V̇	
, or computed 
from the moments of a (multimodal) V̇	
/Q̇ distribution. While it would be possible to 
assign every V̇	
/Q̇ compartment a unique mitochondrial P50 (see equation 5, Figure 1), 
this has not been modeled to date, and P50 has been taken to be constant throughout any single 
muscle. Also as in the lung, diffusion is considered in every V̇	
/Q̇  unit, with the diffusing 
capacity DM distributed in proportion to Q̇, just as for the lung. The algorithm however can 
accommodate different values across compartments for both P50 and DM if desired. The same 
forward integration procedure is used as in the prior model (Cano et al., 2013), when it was 
applied to the entire muscle considered as one homogeneous unit to compute each muscle 
compartment’s effluent venous O2 and CO2 levels for the given inflowing arterial blood 
composition, and the V̇	
/Q̇  and DM/Q̇ ratios of the unit. Again as in the lung, the effluent 
venous blood from all muscle units is combined, or mixed, in terms of both O2 and CO2 
concentrations, and a resulting mixed muscle venous P and P: is then calculated. Finally, 
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this blood is mixed with that from the non-exercising tissues (see below). This mixed venous 
blood returns to the lungs for re-oxygenation. 
In summary, to allow for V̇	
/Q̇ heterogeneity, the single homogeneous muscle 
“compartment” in the prior model has been replaced by a multi-compartment model which 
allows for both V̇	
/Q̇ inequality and diffusion impairment. Similarly to the prior model, 
necessary additional inputs remain the composition of arterial blood, and the blood binding 
characteristics of O2 and CO2. The output remains the composition of mixed muscle venous 
blood destined for return to the lungs for re-oxygenation.      
2.4 Modeling metabolism and blood flow to non-exercising tissues 
Non-exercising tissue blood flow and metabolism are incorporated simply by assigning 
values for total non-exercising tissue V̇ and Q̇, and using the Fick principle to compute the 
tissue venous O2 concentration.  Then, a mixing equation combines venous blood from this 
non-exercising tissue with that from the mixed muscle venous blood (see above) in proportion 
to the blood flow rates assigned to the non-exercising tissues and muscles respectively, to 
form what will be pulmonary arterial blood reaching the lungs for re-oxygenation. 
2.5 Achieving a solution for the model 
In the prior model it was explained (Cano et al., 2013) how the model was run and a solution 
achieved. The same process is used with the above-described expansions in the current paper. 
In brief, a starting estimate is made for the composition of mixed venous blood entering the 
lungs, and for that estimate, the lung component is executed over the many 
V̇	/Q̇ compartments and the end-capillary O2 and CO2 concentrations averaged over all 
compartments (weighted by compartmental blood flow) to yield an estimate of systemic 
arterial P and P:. These are then used as input data for the muscle part of the system, and 
that component is run once for each V̇	
/Q̇ compartment. The effluent compartmental 
venous O2 and CO2 levels are then averaged (again blood flow-weighted), and mixed with the 
blood draining the non-exercising tissues (see 2.4).  It is the P and P: of this mixed blood 
that is the new estimate at mixed venous P and P: for the next iteration (or cycle) of 
pulmonary gas exchange: To this point, all that has changed between the first and second 
cycles is the composition of mixed venous blood. After pulmonary gas exchange calculations 
using this new venous blood composition are complete, new values of arterial blood P and 
P: are calculated, and now muscle O2 exchange is recomputed, from which new values of 
mixed venous P and P: are calculated. This cycling back and forth between the lungs and 
the tissues is continued until the five V̇ estimates - one computed from each of the 5 
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equations in Figure 1 - are identical (to within +/- 0.1 ml/min). At this point, stability of all 
P values (alveolar, arterial, muscle venous and mitochondrial) in the face of further cycling 
between the lungs and tissues is also achieved. When this is observed, the governing 
requirement for conservation of mass has been achieved, and this signals the end of the run. 
2.6 Analysis and input data for simulations 
As mentioned, four questions were posed: 
First, in health, we first assessed the effects of a wide range of lung and tissue heterogeneities 
on oxygen tensions and utilization at all steps of the O2 pathway. This extensive exploration 
was carried out for conditions of maximal exercise breathing room air at sea level. To this 
end, input data defining O2 transport conductances (i.e., ventilation, cardiac output, lung and 
muscle diffusional conductances) from normal subjects exercising maximally at sea level in 
Operation Everest II (Sutton et al., 1988) were used just as for the previous models (Wagner, 
1993, 1996). Lung heterogeneity was analyzed from complete homogeneity (log SD Q̇ = 0), 
to very high inhomogeneity (log SD Q̇ = 2) as might be seen in the critically ill. We also 
explored the effects of skeletal muscle heterogeneity on overall O2 uptake (VO2 max) using 
a similar wide range of log SD V̇68; , from 0 to 2.0..  
However, in all the subsequent analyses, for each level of lung heterogeneity (from 
log SD Q̇ = 0 to log SD Q̇ = 2), the impact of muscle tissue heterogeneity was assessed from 
a completely homogenous exercising muscle (log SD V̇68; = 0), to a likely high degree of 
muscle metabolism/perfusion inhomogeneity (log SD V̇68; = 0.5), taking into account that 
recent experimental studies suggests a  log SD V̇68; of only 0.1 in normal subjects exercising 
maximally at sea level (Vogiatzis et al, J. Applied Physiol, under review)).  
The second question examined the effects of heterogeneity in healthy lungs and muscle on 
O2 transport and utilization at altitude. For the lung we used log SD Q̇ = 0.5 as a value 
commonly seen during exercise (Wagner et al., 1987b). This value is near the upper end of 
the normal range, which is 0.3-0.6 (Wagner et al., 1987a). In muscle, we used preliminary 
unpublished estimates of log SD V̇68; = 0.1. For non-exercising body tissues we used typical 
resting total values of V̇ (300 ml/min), V̇: (240 ml/min) and blood flow (5 L/min) for 
normal subjects. The input data defining the O2 transport conductances again came from 
normal subjects exercising maximally at sea level and altitude in Operation Everest II (Sutton 
et al., 1988) as used above and also in our prior work 2013. However, to study the 
consequences at more altitudes than were examined in Operation Everest II (which were sea 
level, 4600m, 6100m, 7600m and 8848m), O2 transport conductance parameters were linearly 
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interpolated at 305m (1000 ft.) elevation increments from the data obtained at each of the 5 
altitudes studied in Operation Everest II (Sutton et al., 1988). 
Data from experimental human exercise studies do not exist for the two variables defining 
the hyperbolic mitochondrial respiration curve: V̇68; and P. Therefore, we executed the 
simulations mentioned above using a value for V̇68; (4.6 L/min) that is 20% higher than the 
measured V̇max at sea level in Operation Everest II (Sutton et al., 1988) of 3.8 L/min. We 
chose this value as a reasonable estimate for V̇68; because it is known that measured V̇68; 
is less than mitochondrial capacity to use O2 (i.e., V̇	
) in healthy fit subjects since exercise 
capacity is known to be increased when breathing 100% O2 (Welch, 1982; Knight et al., 
1992). For P, we used a value of  0.3 mm Hg, similar to what has been found experimentally 
in vitro (Wilson et al., 1977; Gnaiger et al., 1998; Scandurra & Gnaiger, 2010). Little is known about 
V̇	
/Q̇ heterogeneity in muscle except for measurements made by Richardson using 
magnetic resonance spectroscopy (Richardson et al., 2001) and recent unpublished data using 
NIRS that yield dispersion values of about 0.1 as explained earlier.  
For the third and fourth question we assessed how substantial variations of the three least 
well-established determinants of O2 flux and partial pressures in the transport/utilization 
pathway (V̇	
 and P50 of the mitochondrial respiration curve and log SD V̇	
) would affect 
both V̇ and mitochondrial P estimates, in health (third question) and in COPD (fourth 
question). Input data defining O2 transport conductances and lung heterogeneity 
(i.e. log SD Q̇ = 0.5) from normal subjects exercising maximally at sea level in Operation 
Everest II (Sutton et al., 1988) were used in health. In disease, measured O2 conductances and 
lung heterogeneity data came from two previously studied COPD patients (Blanco et al., 
2010) exercising maximally (Table II), one with mild (FEV1 = 66 % predicted post-
bronchodilator) and one with severe (FEV1 = 23 % predicted post-bronchodilator) COPD. 
However, even if reasonable, the values of V̇	
 and P50 assumed to answer the previous 
question are uncertain, let alone whether there is significant V̇	
/Q̇ heterogeneity. Because 
of this, we carried out simulations over a wide range of possible values of these variables. In 
the case of  V̇68;, it is known that acutely increasing inspired O2 concentration increases 
exercise capacity, both in health and in COPD (Welch, 1982; Knight et al., 1992; Richardson 
et al., 2004). How much higher is not known, and so to determine how important knowing 
V̇	
 is to the outcomes of the model we compared outcomes using the previously-used 
V̇	
 value (20% higher than actual V̇68;) to results obtained when V̇	
 was set to 10 % 
and 30% above measured V̇68;. For mitochondrial P50, we used values lower (0.14 mm 
Hg) and higher (0.46 mm Hg) than 0.3 mm Hg, the value found experimentally in vitro (Wilson 
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et al., 1977; Gnaiger et al., 1998; Scandurra & Gnaiger, 2010). Finally, to assess how sensitive the 
outcomes are to the degree of heterogeneity, we also carried out calculations with 
log SD V̇	
 values of 0.1 (healthy subject estimates), 0.2 and 0.3. With respect to non-
exercising body tissues, we used typical resting total values of V̇ (300 ml/min), V̇: (240 
ml/min) and blood flow (5 L/min) for normal subjects.  
For the two previously studied COPD patients (Blanco et al., 2010) exercising maximally we 
used measured resting values of whole body V̇ (V̇rest) and V̇: (Table II), along with 
a blood flow estimate (Q̇BCBEGJGKRUWUBX) from the following formula, which expresses the 
concept that blood flow is proportional to metabolic rate: Q̇BCBEGJGKRUWUBX =  Q̇68; ∗
V̇rest V̇max . 
3. Results 
3.1. Effects of potential lung and muscle heterogeneities on O2 transport and utilization in 
healthy subjects exercising maximally at sea level 
Figure 2 shows the independent effects of lung V̇	/Q̇ heterogeneity (solid circles) and muscle 
V̇	
/Q̇ heterogeneity (empty circles) on maximal muscle oxygen uptake (V̇max), in 
normal subjects exercising maximally at sea level. In this figure, both V̇	/Q̇ and V̇	
/Q̇ 
heterogeneity has been varied over a wide range of LOG SD, from 0 to 2.0. Healthy subjects 
show pulmonary log SD Q between 0.30 and 0.60 (refs), whereas skeletal muscle 
heterogeneity (log SD Vmax) presents a average value of 0.10 (Vogiatzis et al, J. Applied 
Physiol, under review). In patients with moderate to severe COPD, log SD Q can present 
values close to 1.0, but no published data on log SD Vmax are available. However, recent 
studies in patients with COPD (Louvaris et al, in preparation) suggest similar degrees of 
muscle heterogeneity as in health. Finally, critically ill patients admitted in the Intensive Care 
Unit (ICU) may show lung heterogeneity values close to 2.0, but no information on log SD 
Vmax is available.  The main result from Figure 2 is that for any given degree of 
heterogeneity, that in muscle affects O2 transport more than does that in the lungs. However, 
because muscle heterogeneity appears to be much less than that in the lung, both in health 
and COPD, based on a combination of published and unpublished data as mentioned, actual 
muscle heterogeneity has less of an impact on O2 transport than observed lung heterogeneity. 
The six panels in Figure 3 display the estimated (combined and separate) effects of lung and 
muscle heterogeneities on the O2 transport and utilization system. The upper-left panel 
indicates arterial P(P87 ) over a range of exercising muscle V̇	
/Q̇ mismatching (0 to 0.5), 
expressed as log SD V̇68;. For each log SD V̇68; value, the panel displays P87 values for 
different  levels of lung V̇	 Q̇⁄   heterogeneity, from the homogeneous lung (log SD Q̇ = 0) to 
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a highly heterogeneous lung (log SD Q̇ = 2). Each line represents the outcome at a given level 
of lung heterogeneity over a range of muscle heterogeneity. This panel shows that muscle 
heterogeneity has only a small effect on P87  at all levels of lung functional heterogeneities. 
However, as is well known, V̇	/Q̇ inequality has a major impact on arterial oxygenation as 
shown. Likewise, the upper-right panel shows the effects of muscle heterogeneity on effluent 
muscle venous P (PZ7 ). The impact is moderate, and is greater than the effect on P87 . 
However, it is quantitatively important only at high levels of tissue heterogeneity, especially 
in combination with lungs containing little heterogeneity.  
The two middle panels of Figure 3 show the relationships between mitochondrial P  (P67 ) 
and skeletal muscle V̇	
/Q̇ heterogeneity. The left hand panel shows the lowest 
compartmental values of P67  (i.e., when V̇	
/Q̇ is high) and the right hand panel shows 
the highest compartmental values of P67  (i.e., when V̇	
/Q̇ is low). Note that the ordinate 
scales are very different in these two panels. These panels show that heterogeneity of 
V̇	
/Q̇ ratios markedly expands the range of P67 levels among exercising skeletal muscle 
compartments. As in the top panels, each line in the two middle panels correspond to different 
levels of lung heterogeneity from a homogeneous lung (log SD Q̇ = 0) to a highly 
heterogeneous lung (log SD Q̇ = 2).  
The left middle panel shows that, as expected, the greater the peripheral heterogeneity, the 
lower the minimum P67 values. Moreover, we observe a moderate impact of lung 
heterogeneity on minimum P67 , but such impact decreases as skeletal muscle heterogeneity 
increases. Likewise, the right middle panel shows that skeletal muscle compartments with 
lowest V̇	
/Q̇  ratios may generate exceedingly high  P67 estimates that increase with tissue 
heterogeneity. Homogeneous lungs show the highest  P67  values for a given level of 
peripheral tissue heterogeneity. 
The lower left panel indicates that muscle heterogeneities have small effects on total 
muscle V̇, especially compared with lung heterogeneities that show a significant impact on 
muscle V̇max. Finally, the lower right panel displays the maximum estimates for 
compartmental muscle P67  (as seen in the middle right panel of the same figure) plotted 
against the corresponding mean effluent muscle PZ7  (from the top right panel). The 
individual lines indicate different levels of muscle heterogeneities, from a homogeneous 
tissue (SDVmax = 0) at the bottom to heterogeneous muscle (SDVmax = 0.5) at the top. In 
the panel, the dashed straight line corresponds to the identity line. The point of presenting this 
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relationship is to show that when the dispersion of muscle V̇	
 is 0.2 or greater, some regions 
of muscle will have mitochondrial P values that exceed P of the effluent muscle venous 
blood.   
 
3.2. The role of functional heterogeneities, lung and muscle, on O2 transport and utilization 
in healthy subjects at altitude 
The four panels in Figure 4 display the effects of altitude on four key outcome  variables at 
maximal exercise – arterial, muscle venous, and mitochondrial P and V̇68; itself. Two 
relationships are shown in each panel – that computed in the absence of either lung or muscle 
heterogeneity, and that computed allowing for reasonable normal estimates of heterogeneity 
in each location as listed above in the methods section (V̇	/Q̇ heterogeneity in the lung 
quantified by a dispersion value (log SD Q̇) of 0.5, V̇	
/Q̇ heterogeneity in muscle 
quantified using an estimate of dispersion (log SD V̇	
) of 0.1, and non-exercising body 
tissues using typical resting total values of V̇ (300 ml/min), V̇: (240 ml/min) and blood 
flow (5 L/min)). Except for arterial P at sea level and altitudes up to about 10,000ft, the 
effects of typical levels of heterogeneity are seen to be small, and diminish progressively with 
increasing altitude. 
3.3. Sensitivity of outcomes to mitochondrial respiration and muscle heterogeneity estimates 
in health 
Recall that the three least well established determinants of O2 flux and partial pressures in the 
transport/utilization pathway are the V̇	
 and P50 of the mitochondrial respiration curve (that 
links V̇ to mitochondrial P ) and the extent of muscle heterogeneity. Because of this, we 
carried out calculations of how variation in their assumed values would affect both V̇ and 
mitochondrial P estimates. In the preceding sections we assumed a value for V̇	
 20% 
above measured V̇68;. In this section, we now use values of V̇68; + 10% and V̇68; + 
30%. For mitochondrial P50 (assumed normal value 0.3 mm Hg (Wilson et al., 1977; Gnaiger et 
al., 1998; Scandurra & Gnaiger, 2010)), we also used values of 0.14 and 0.46 mm Hg. With 
heterogeneity of V̇	
 estimated at 0.1 (log SD V̇	
), we also used values of 0.2 (moderate 
heterogeneity) and 0.3 (severe heterogeneity). This yielded 3x3x3 or 27 combinations of these 
variables. It should also be noted that the values chosen reflect substantial relative differences 
for each variable.  
Figure 5 shows the results of this analysis in a format where predicted V̇68; is plotted 
against the corresponding predicted average muscle mitochondrial P so that the effects can 
be seen for both of these outcome variables. The top panel shows results when V̇	
 = 
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V̇68; + 10%; the middle panel for V̇	
 = V̇68; + 20% and the lower panel for V̇	
 = 
V̇68; + 30%. In each panel, open squares represent P50 = 0.14 mm Hg, closed circles a P50 
of 0.3 mm Hg and open triangles a P50 of 0.46 mm Hg. For any one such P50, the three 
connected points in each case reflect, from left to right, log SD V̇	
 = 0.1 (normal), 0.2 
(moderate), and 0.3 (severe heterogeneity). 
In terms of predicted V̇68;, the consequences of these uncertainties are small. The highest 
V̇68; in all three panels is 3415 ml/min, and the lowest is 3192 ml/min. However, in terms 
of mean mitochondrial P , the effects are greater. P67 is systematically higher for the lowest 
V̇	
 (range of P67 : 0.8 to 3.7 mm Hg, top panel) to lower panel (highest V̇	
, range of 
P67 : 0.3 to 1.9 mm Hg). At any V̇	
, increasing mitochondrial P50 results in systematically 
higher P67 values, however, with almost no effect on the relationship between V̇68; and 
P67 . Finally, increasing V̇	
 heterogeneity raises average P67 for any set of V̇	
 and P50 
values. 
3.4. Simulated impact of lung and muscle heterogeneity on &.-and muscle !̇- in two 
patients with COPD of different severity: Question 4 
As Table 2 shows, lung heterogeneities had been measured in each patient using the multiple 
inert gas elimination technique (Blanco et al., 2010). The first patient displays features that 
would be regarded as reflecting moderate COPD, while the second patient represents end-
stage COPD and extremely limited exercise capacity.   
Figure 6 displays the impact of functional lung and muscle heterogeneities on the O2 pathway 
in the two COPD patients (moderate severity, left panels and end stage severity, right panels). 
The format indicates the values of both predicted V̇68; and P67 over a range of values of 
the same three least certain variables (V̇	
 and P50 of the mitochondrial respiration curve 
and degree of muscle V̇	
 heterogeneity, none of which are known for these patients).  
The less affected patient (left three panels) behaves in a fashion very similar to that shown in 
Figure 5 for normal subjects (other than for absolute values of peak V̇ under all conditions). 
In particular, mitochondrial P values are in the same range as for normal subjects. Variation 
in P67 across muscle regions is considerable (not shown) with a SD of 10 mm Hg. 
For the severely affected patient (right three panels), peak V̇ is insensitive to substantial 
changes in mitochondrial V̇	
, P50 or the extent of heterogeneity. Only mitochondrial P50 
changes will have some effect on mitochondrial P , but it is important to note that the scale 
of mitochondrial P is very different than normal, and is far lower under all conditions, with 
little variation throughout the muscle (SD of 1 mm Hg). 
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4. Discussion 
4.1. Summary of major findings 
 
This study has generated the first integrated model of the O2 pathway that takes into account 
all the individual components of O2 transport and utilization considering both exercising and 
non-exercising tissues at V̇max in health and in disease (i.e. COPD), thus allowing for 
heterogeneity in both lungs and muscle.  
The research addresses the separate and combined contributions of functional heterogeneities 
at pulmonary and at skeletal muscle levels to each of the components of the O2 pathway. 
Emphasis is placed on estimating the impact of lung and skeletal muscle V̇	
/Q̇ ratio 
inequalities on overall muscle V̇ and on mitochondrial P at maximal exercise. This was 
done simulating normal subjects at sea level and altitude, and patients with COPD. The main 
findings are that, muscle heterogeneity, at a given log SD (Figure 2), shows higher potential 
to affect maximal O2 availability than does lung V̇	/Q̇ inequality. Moreover, V̇	
/
Q̇ heterogeneity results in a wide range of potential mitochondrial P values – a range that 
could have implications for muscle function as discussed below. These findings stress the 
relevance of performing further measurements of  skeletal muscle heterogeneities in health 
and disease.  
4.2. Implications of functional heterogeneities: lung and skeletal muscle  
 
Whether arterial oxygenation falls as a result of altitude in normal subjects or as a result of 
heterogeneity in the lungs in patients with lung disease (at sea level), it is clear that O2 
availability to the muscles must fall. This has been appreciated for many years, as has the 
consequence of such reduced O2 availability for maximal exercise capacity. The other 
potentially important consequence of reduced O2 availability is reduced mitochondrial P . 
This may have more than one effect on cellular function. 
While heterogeneity in the lungs must cause mitochondrial P to fall throughout the muscle 
(all other factors unchanged), heterogeneity in the muscles will additionally cause 
mitochondrial P to vary between muscle regions. In those areas with higher than average 
V̇	
 in relation to blood flow, mitochondrial P is lower than average, but in regions where 
V̇	
 is low in relation to blood flow, mitochondrial P must rise to levels greater than would 
be seen in the absence of heterogeneity. The consequences of subnormal mitochondrial P are 
discussed below. There may be corresponding functional consequences of a high 
mitochondrial P as well.  
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A high P may oppose vasodilatation and restrict local perfusion, thus increasing the V̇	
/Q̇ 
back towards normal and offering an intrinsic mechanism to automatically limit mitochondrial 
P heterogeneity. A high mitochondrial P will also reduce the capillary to mitochondrial 
P diffusion gradient, reducing diffusive O2 transport and again working towards restoring 
the balance between O2 supply and demand. Furthermore, the high P may exert genomic 
effects that may be opposite to those expected when P is below normal (see above). The 
potential therefore exists for regional regulation of gene expression (and thus for adaptive 
programs) according to local P . Finally, when mitochondrial P is elevated, the potential 
exists for increased ROS generation, just as when P is below normal. If so, muscle regions 
with both very low and very high V̇	
/Q̇ ratios may be at risk of oxidative stress. 
4.3 Biological and clinical implications 
The multilevel impact of disturbances of cellular oxygenation on cell function is well 
recognized (Semenza, 2011). Hypoxia- (or hyperoxia-) induced biological alterations may 
play a significant role on underlying mechanisms in different acute and chronic conditions 
(Resar et al., 2005). A major conclusion of the present study is that mitochondrial P  will 
vary considerably among muscle regions of different V̇	
/Q̇ ratio. When V̇	
/Q̇ is low, 
P67 is high, and vice versa. This potential variation in P67 may have significant biological 
implications.  
First, since a low P facilitates local vasodilatation in muscle (Rowell, 1986), those areas with 
high V̇	
 in relation to Q̇, thus having a low P67 , may preferentially vasodilate, which 
means that Q̇ may increase locally and that the V̇	
/Q̇ ratio is thus, in part, normalized. In 
this way, V̇	
/Q̇ heterogeneity may be to some extent self-limited. This corresponds to 
hypoxic pulmonary vasoconstriction in the lungs, where it has been known for many years that 
a region with a low V̇	/Q̇ ratio will vasoconstrict, limiting blood flow and tending to push the 
V̇	/Q̇ ratio back towards normal.  
Second, the lower the mitochondrial P, the higher will be the P difference between the 
muscle microvasculature and the mitochondria, other factors equal. This facilitates the 
diffusion process, and provides an additional, automatic compensatory mechanism to work in 
the direction of restoring V̇ when blood flow is low. Whether these self-correcting effects 
are seen in disease remain to be determined.   
Third, a low P may have implications for genomic responses. As P falls in regions with 
high V̇	
/Q̇ ratios, the HIF system may be activated, preferentially in those regions, signaling 
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adaptive changes to enhance key processes such as glucose transport, glycolysis and 
angiogenesis. It may also have implications for differential reactive oxygen species (ROS) 
generation across muscle fibers, since it appears that ROS generation is P dependent 
(Selivanov et al., 2012). Regions with a low V̇	
/Q̇ and thus a high mitochondrial P may be 
hyperoxic to the point of inducing regional cellular damage from high ROS levels.  These 
speculative predictions will of course need to be examined experimentally in the future. 
4.4. Potential for estimating &.- in health and in disease  
It may be possible to measure mitochondrial P  (P67 ) in the future (Mik, 2013) but this 
promising approach is not yet generally available.  If this, or another, method can be developed 
into a feasible approach for intact humans, it offers the potential for estimating, at least 
approximately, the parameters of the in vivo mitochondrial O2 respiration curve. By varying 
inspired O2 concentration over as wide a range as safely possible, paired values of V̇ and 
P67 could be measured, and if they were to bracket both the O2-dependent and O2-independent 
regions of the mitochondrial respiration curve, there may be enough information to estimate 
V̇	
 and P50.  
4.5. Limitations of the analysis 
Firstly, as in previous work (Wagner, 1993, 1996; Cano et al., 2013), the entire analysis applies 
to steady state conditions (meaning, that O2 partial pressures are constant in time, as is V̇ 
itself). Therefore, the analyses should not be extrapolated to transient changes in metabolic 
rate at the beginning or end of exercise. Additional limitations are that for this modeling 
approach to apply with accuracy, parameters defining the in vivo mitochondrial respiration 
curve (again, V̇	
 and P50) are required. While the degree of V̇	/Q̇ heterogeneity in the lungs 
of individual subjects or patients has been measurable for many years, that in the muscle is not 
directly accessible by any yet published method. Thus, for the present paper, the estimates 
used are uncertain, and the quantitative outcomes should not be generalized - they are specific 
to the particular input variables we used. That is why we elected to run simulations over a 
range of the most uncertain variables. That said, given that the principal objective of our study 
was to present the development of an O2 transport model that encompasses heterogeneity in 
both lungs and muscle, it seems reasonable to illustrate its prediction capabilities, even if 
estimates of some input variables are uncertain. With the algorithm now developed, running 
the simulations with accurate data when available will easily be possible. The quantitative 
results presented thus show the impact of heterogeneity for the specific cases simulated.  
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5. Conclusions 
The current research includes consideration of functional heterogeneities (lung and muscle), 
as well as the O2 consumed by non-exercising tissues, in a previously established integrative 
O2 pathway model. It allows application of the modeling approach to patients with chronic 
diseases such as COPD, and reveals the interplay among lung V̇	/Q̇ heterogeneity and skeletal 
muscle mismatching on VO2max. Moreover, skeletal muscle V̇	
/Q̇ ratio  inequality creates 
regions with either very high or very low intracellular PO2 values with potentially multiple 
biological consequences, some potentially beneficial and some possibly harmful. 
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Tables 
TABLE I – Input parameters for the modeling of the oxygen transport system in health at sea 
level and altitude 
 
 
Altitude 
(ft.) 
Barometric 
pressure 
(), Torr 
Body 
temperature 
(\), °C 
Hemoglobin 
concentration 
([^_]),  g·dl-1 
Alveolar 
ventilation 
(`̇), BTPS, 
L·min-1 
Blood 
flow (ḃ), 
L·min-1 
Total 
Lung O2 
diffusing 
capacity 
(df), 
ml·min-
1·Torr-1 
Total 
muscle O2 
diffusing 
capacity 
(dh), 
ml·min-
1·Torr-1 
0 760 38 14,2 128,3 25,0 50,9 104,6 
5000 639 38 14,9 137,1 23,5 60,9 97,1 
10000 534 38 15,5 145,9 22,0 70,9 89,6 
15000 442 38 16,2 154,6 20,5 80,9 82,1 
16000 426 37,9 16,3 156,4 20,2 82,9 80,6 
17000 410 37,8 16,5 158,1 19,9 84,9 79,1 
18000 394 37,7 16,6 159,9 19,6 86,9 77,6 
19000 380 37,6 16,7 161,6 19,3 88,9 76,1 
20000 365 37,5 16,9 163,4 19,0 90,9 74,6 
21000 351 37,4 17,0 165,2 18,7 92,9 73,1 
22000 337 37,3 17,1 166,9 18,4 94,9 71,6 
23000 324 37,2 17,2 168,7 18,1 96,9 70,1 
24000 311 37,1 17,4 170,4 17,8 98,9 68,6 
25000 299 37 17,5 172,2 17,5 100,9 67,1 
26000 286 37 17,6 173,9 17,2 102,9 65,6 
27000 275 37 17,8 175,7 16,9 104,9 64,1 
28000 264 37 17,9 177,4 16,6 106,9 62,6 
29000 253 37 18,0 179,2 16,3 108,9 61,1 
30000 243 37 18,2 181,0 16,0 110,9 59,6 
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TABLE II – Input parameters for the modeling of the oxygen transport system in disease 
(moderate and severe COPD) 
 
 
 
 
 
 
 
 
 
 
Parameter Moderately 
limited 
transport 
Severely  
limited  
transport 
Forced Expired Volume in the 1st second (i!j), % predicted 
post-bronchodilator 66 23 
Forced Vital Capacity ( !k), % predicted post-
bronchodilator 84 
33 
i!j !k⁄  0.60 0.54 
Log SD "̇ 0.67 0.86 
Barometric pressure (&n), Torr 758 765 
Fractional Inspired Oxygen (-) 0.2093 0.2093 
Hemoglobin concentration ([#$]),  g·dl-1 14.4 12.5 
Body temperature (%), °C 37.0 36.8 
O2 dissociation curve &'( , Torr 26.8 26.8 
Resting ventilation (!̇), BTPS, L·min-1 7.11 7.44 
Resting cardiac output ("̇), L·min-1 3.68 3.20 
Resting !̇-,  ml·min-1 235 159 
Resting !k̇-,  ml·min-1 174 103 
Resting arterial &-  (&/- ), mm Hg 80 59 
Resting arterial &k-  (&/k-), mm Hg 35 46 
Resting lactate, mmol·L-1 1.47 0.81 
Exercise ventilation (!̇), BTPS, L·min-1 35.3 8.2 
Exercise cardiac output ("̇), L·min-1 7.75 3.98 
Exercise !̇-,  ml·min-1 914 355 
Exercise arterial &-  (&/-), mm Hg 90 59 
Exercise arterial &k-  (&/k- ), mm Hg 31 49 
Exercise Lung O2 diffusing capacity ()*), ml·min-1·Torr-1 100 11 
Exercise muscle O2 diffusing capacity (),), ml·min-1·Torr-1 26 9 
Exercise lactate, mmol·L-1 3.55 2.03 
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Figures and legends 
 
Figure 1: Schematic representation of the oxygen transport and utilization system and the five 
associated mass conservation equations governing O2 transport (Eqs. (a)-(d)) and utilization (Eq. 
(e)). 
 
 
Figure 2: Independent effects of lung V̇	/Q̇ heterogeneity (solid circles) and muscle V̇	
/Q̇ 
heterogeneity (empty circles) on maximal muscle oxygen uptake (V̇max), using input data 
defining O2 transport conductances (i.e., ventilation, cardiac output, lung and muscle diffusional 
conductances, etc.) from normal subjects exercising maximally at sea level in Operation Everest 
II (Sutton et al., 1988). Healthy subjects show pulmonary log SD Q̇ between 0.3 and 0.6 (Wagner 
et al., 1974), whereas skeletal muscle heterogeneity (log SD V̇	
) presents an average value of 
0.10 (Vogiatzis et al, J. Applied Physiol, under review). In patients with moderate to severe 
COPD, log SD Q̇ can present values close to 1.0, but no published data on log SD V̇	
 are 
available. However, recent studies in patients with COPD (Louvaris et al, in preparation) suggest 
similar degrees of muscle heterogeneity as in health. Finally, critically ill patients admitted in the 
Intensive Care Unit (ICU) may show lung heterogeneity values close to 2.0. Again, no 
information on log SD V̇	
 is available.    
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Figure 3: Combined and separated effects of lung and exercising muscle heterogeneities on the 
O2 transport pathway: on arterial blood (upper-left panel), venous blood (upper-right panel) and 
mitochondria (two central panels), maximal muscle oxygen uptake (lower-left panel), and, 
maximum degree of oxygen unbalance between mitochondrial P  of muscle compartments and 
mean effluent venous (PZ7 ) oxygen levels (lower-right panel). See text for details. 
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Figure 4: Effects of functional inhomogeneity on arterial P  (upper left panel), venous P  
(upper right panel), mitochondrial P  (lower left panel) and V̇ (lower right panel) at sea level 
and altitude. Functional inhomogeneity is expressed as the combined effects of lung ventilation-
perfusion inequalities and skeletal muscle perfusion-metabolism mismatching. Mitochondrial 
respiration parameters were fixed to a V̇	
 of 4,584 ml/min and a P of 0.3 mm Hg. Filled 
circles correspond to simulations outputs when considering both homogeneous lung and tissues. 
Empty circles represent simulation outputs when using reasonable estimates for lung ventilation-
perfusion (log SD Q̇ of 0.5), tissue perfusion-metabolism (log SD V̇	
 of 0.1), and the metabolic 
rate of non-exercising tissues (with an assigned V̇ of 300 ml/min, a V̇: of 240 ml/min) and 
assuming that 20% of total blood flow goes to non-exercising tissues. See text for details. 
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Figure 5: Effects of muscle bioenergetics (mitochondrial respiration V̇	
 and P parameters) 
and muscle peripheral heterogeneities on muscle V̇ and mitochondrial P (P67 ) in health at 
sea level. V̇	
 is taken as 10% (upper panels), 20% (middle panels) and 30% (lower panels) 
greater than measured V̇max. For each V̇	
, three mitochondrial P values (0.14, 0.3 and 0.46 
mm Hg) and three degrees (0.1, 0.2 and 0.3) of muscle perfusion-metabolism inhomogeneity 
(log SD V̇	
) were evaluated. See text for details. 
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Figure 6: Effects of muscle bioenergetics (mitochondrial respiration V̇	
 and P parameters) 
and muscle peripheral heterogeneities on muscle V̇ and mitochondrial P (P67 ) for given 
representatives of mild (left-side panels) and severe (left-side panels) limitation of O2 transport 
conditions in chronic obstructive pulmonary disease (COPD). V̇	
 is taken as 10% (upper 
panels), 20% (middle panels) and 30% (lower panels) greater than measured V̇max in the two 
COPD patients exercising maximally, selected as representatives of both mild and severe O2 
transport conditions. For each V̇	
, three mitochondrial P values (0.14, 0.3 and 0.46 mm Hg) 
and three degrees (0.1, 0.2 and 0.3) of muscle perfusion-metabolism inhomogeneity 
(log SD V̇	
) were evaluated. See text for details. 
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ABSTRACT 
The production of reactive oxygen species (ROS) from the inner mitochondrial membrane is one 
of many fundamental processes governing the balance between health and disease. It is well 
known that ROS are necessary signaling molecules in gene expression, yet when expressed at 
high levels, ROS may cause oxidative stress and cell damage. Both hypoxia and hyperoxia may 
alter ROS production by changing mitochondrial P (P67 ). Because P67  depends on the 
balance between O2 transport and utilization, we formulated an integrative mathematical model 
of O2 transport and utilization in skeletal muscle to predict conditions to cause abnormally high 
ROS generation. Simulations using data from healthy subjects during maximal exercise at sea 
level reveal little mitochondrial ROS production. However, altitude triggers high mitochondrial 
ROS production in muscle regions with high metabolic capacity but limited O2 delivery. This 
altitude roughly coincides with the highest location of permanent human habitation. Above 
25,000 ft., more than 90% of exercising muscle is predicted to produce abnormally high levels 
of ROS, corresponding to the “death zone” in mountaineering. 
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1. Introduction  
It is well accepted that cellular hypoxia [1-4] triggers a constellation of biological responses 
involving transcriptional and post-transcriptional events [5, 6] through activation of cellular 
oxygen sensors. This includes generation of reactive oxygen species (ROS). Yet, current 
knowledge on the quantitative relationships between mitochondrial P (P67 ), hypoxia-
induced cellular events, and on the release of ROS from the inner mitochondrial membrane, is 
minimal.  For example, how low P67  must be to trigger abnormally high ROS generation has 
not yet been identified. Furthermore, the levels of P67  at rest and during exercise are unknown, 
although myoglobin-associated P has been measured in intact excising humans [7, 8], and is 
reported to be 3-4 mm Hg, implying that P67  is likely even lower. There are promising new 
approaches being developed to in vivo assessment of P67  [9]. 
Recently, we extended a prior model describing O2 transport from the air to the mitochondria 
as an integrated system limiting maximal oxygen uptake V̇	
 [10, 11] to also include the 
contribution to overall impedance to O2 flow from the above-zero P67  required to drive 
mitochondrial respiration [12]. This was accomplished by including an equation for the 
hyperbolic relationship between mitochondrial Pand mitochondrial V̇ as shown by Wilson 
et al. [13] and confirmed more recently by Gnaiger’s group [14, 15]. This has enabled the 
prediction of P67  as a balance between the capacities for muscle O2 transport and utilization 
[12, 16]. In addition, we have expanded this model by now allowing for functional heterogeneity 
in both lungs and muscle [16], which had previously (and reasonably) been taken to be negligible 
in health. This was done to enable application to disease states. Since mitochondrial ROS 
generation is affected by cellular oxygenation, this integrative model may afford the opportunity 
for better understanding the quantitative relationship between O2 transport, mitochondrial 
respiration and ROS generation, provided we have an understanding of the relationship 
between P67  and ROS formation.  
Recent modeling and experimental studies on mitochondrial ROS production under hypoxia and 
re-oxygenation [17-19] have proposed an inherent bi-stability of Complex III, i.e. coexistence of 
two different steady states at the same external conditions: one state corresponding to low ROS 
production, and a second potentially dangerous state with high ROS production. Temporary 
deprivation of oxygen could switch the system from low to high ROS production, thus explaining 
the damaging effects of hypoxia-re-oxygenation. This recently proposed model provides a 
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conceptual basis for the abnormally high ROS production observed both in hyperoxia [20, 21] 
and hypoxia [1-4] and has the ability to predict the quantitative relationship between ROS 
generation and P67 . 
In this paper, we build upon these previous but separate models of O2 transport as a 
physiological system and mitochondrial metabolism as a biochemical system, and have linked 
them through their common variables, P67  and V̇, establishing one integrated model to 
predict P67 and mitochondrial ROS production. Specifically, we integrate the physiological 
model of the oxygen pathway predicting P67 from the balance between O2 transport and 
mitochondrial O2 utilization [10-12, 16] with the model of electron and proton transport in the 
mitochondrial respiratory chain, and the ROS production associated with this transport [17-19], 
thereby predicting the rate of ROS production as a function of P67  and V̇. The former model 
is referred to below as the O2 pathway model, and the latter as the mitochondrial ROS prediction 
model.  
In addition to describing the integrated modeling system, we present estimates of ROS 
generation in exercising muscle of healthy subjects at different altitudes at and above sea level 
using O2 transport data from Operation Everest II [22] and published mitochondrial kinetic data 
in normal human muscle (discussed in [17]). We found that at sea level, O2 transport at maximal 
exercise is sufficient to keep P67  high enough that mitochondrial ROS generation is not 
significantly increased. However, exercise at high altitude is predicted to significantly increasing 
ROS generation, agreeing with experimental data collected under these conditions [23-25]. 
2. Materials and methods 
2.1. Oxygen pathway model 
The modeling of O2 transport and utilization [10-12] adopted in the current article relies on the 
concept that maximal mitochondrial O2 availability is governed by the integrated behavior of all 
steps of the O2 transport and utilization system rather than being  dominated by any one step. 
Building on the work of DeJours [43], and Weibel et al [44], it was previously shown [10, 11] how 
each step (ventilation, diffusion across the alveolar wall, circulation, diffusion from the muscle 
capillaries to the mitochondria, and finally, oxidative phosphorylation itself) contributes 
quantitatively to the limits to maximum O2 uptake (V̇	
). The model is based on the principle 
of mass conservation at every step, and uses the well-known mass conservation equations for 
each step as laid out by Weibel et al [45]. Given the oxygen transport properties of the lungs, 
heart, blood and muscles, and incorporating the (hyperbolic) mitochondrial respiration curve 
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that relates mitochondrial V̇ to mitochondrial P [13-15] the model computes how much O2 
can be supplied to the tissues (V̇), and the partial pressures of oxygen at each step (i.e. alveolar 
(P	7 ), arterial (P87 ), venous (PZ7 ), and mitochondrial (P67 )). This construct [12] leads to a 
system of five equations, each describing mass conservation equations governing O2 transport 
(Eqs. (1) - (4)) and utilization (Eq. (5)), with the five unknowns also mentioned above.  
 
V̇ = V̇I · FI − V̇A · FA (1) 
V̇ = V̇I · FI − V̇A · FA (2) 
V̇ = Q̇Ca − Cv (3) 
d[O](u)
dt =
DM
T · Q̇
· wPc(y) − Pmz 
(4) 
V̇ =
V̇	
 · Pm
Pm + P
 (5) 
However, this system ignores heterogeneity of ventilation/perfusion (V̇	/Q̇) ratios in the lung, 
and heterogeneity of metabolism/perfusion (V̇/Q̇) ratios in the muscle. This is laid out in detail 
in [16], and in the current article, consideration of typical, normal degrees of lung and muscle 
heterogeneity has been incorporated. The original 5-equation model [12] also failed to take into 
account that not all of the cardiac output flows to the exercising muscles. Allowance for blood 
flow to, and O2 utilization by, non-exercising tissues has accordingly also now been incorporated 
into the system described in [16] and is used here. 
2.2. Parameters of the O2 pathway model 
The most complete data set with respect to O2 pathway conductances during exercise at altitude 
(ventilation (V̇A), cardiac output (Q̇), lung (DL) and muscle (DM) diffusional conducances, [Hb]) 
comes from Operation Everest II [22], but even here, measurements were made only at sea 
level, and at barometric pressures equivalent to four specific altitudes of 15,000 ft., 20,000 ft., 
25,000 ft. and 29,000 ft. Because we wished to simulate the entire altitude domain from sea 
level to the Everest summit, we used the Operation Everest II data to interpolate parameter 
values at intervening altitudes. Additional input parameters are required for the analysis. These 
include: a) maximal muscle mitochondrial metabolic capacity (V̇68;), b) mitochondrial P50 i.e., 
the P at which mitochondrial respiration is half-maximal, c) dispersion of ventilation/perfusion 
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ratios in normal lungs, d) dispersion of metabolism/perfusion ratios in muscle, and e) an 
estimate of total blood flow to non-exercising tissues and their corresponding V̇. 
For V̇68;, we chose a value 20% higher than the observed sea level maximal V̇ in the Operation 
Everest II subjects, and this came to 4.58 L/min. The justification is that in healthy fit subjects, 
V̇max is O2 supply-limited at sea level, since it increases when 100% O2 is breathed  [46, 47]. 
This demonstrates that mitochondrial metabolic capacity is clearly greater than sea 
level V̇max.  For mitochondrial P50, a value of 0.14 mm Hg was chosen. This is the 
mitochondrial P50 value used in the ROS prediction model described below [17-19], and is close 
to reported values measured in vitro [14, 15]. A representative normal level of 
ventilation/perfusion heterogeneity (i.e., log SD Q̇ = 0.5) was used, since normal subjects display 
log SD Q̇ values of between 0.3 and 0.6 [26], increasing slightly with exercise.  Log SD Q̇ is the 
second moment (dispersion) of the perfusion distribution on a logarithmic scale and has been 
used to quantify V̇	/Q̇ heterogeneity for about 40 years [48-50]. For V̇/Q̇ heterogeneity in 
muscle, there is very limited information. From a new technique based on near-infrared 
spectroscopy and currently in development, the corresponding dispersion in muscle appears to 
be about 0.1 (Vogiatzis et al, J. Applied Physiol, under review), and this was used.  
Finally, to allow for non-exercising tissue perfusion and metabolism we used typical normal 
resting values of cardiac output and V̇ (specifically, non-exercising total tissue blood flow equal 
to 20% of maximal sea level cardiac output, and V̇ of 300 ml/min). 
2.3. Mitochondrial ROS prediction model   
The mitochondrial ROS prediction model [17-19] considered in this study accounts for: i) 
Respiratory complex I that oxidizes NADH and reduces ubiquinone (Q), translocating H+; ii) 
Respiratory complex II that also reduces Q, oxidizing succinate to fumarate; iii) Respiratory 
complex III, the net outcome of which is to oxidize ubiquinol, reducing cytochrome c and 
translocating H+; iv) Respiratory complex IV that oxidizes cytochrome c, reducing molecular 
oxygen to H2O and translocating H+; and, v) The H+ gradient utilization for ATP synthesis in 
respiratory complex V. NADH consumed by complex I is produced in the several reactions of the 
TCA cycle leading from pyruvate to succinate, and from fumarate to oxaloacetate. 
This model consists of a large system of ordinary differential equations that simulate the 
processes mentioned above based on the general principle of the law of mass action. Simulating 
the redox (from reduced/oxidized) reactions between the electron carriers constituting 
complexes I and III, the model takes into account that the carriers occupy fixed positions and 
have fixed interactions in the space of a respiratory complex. The variables of this model are the 
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concentrations of redox states of the complex. Each redox state of the complex is a combination 
of redox states of the electron carriers constituting it. Since a carrier can be in one of the two 
redox states (reduced or oxidized), the number of variables is 2n, where n is the number of 
electron carriers fixed in the space of the complex. The model accounts also various forms of 
the complexes created by binding/dissociation of ubiquinone/ubiquinol. The other respiratory 
complexes are accounted for in a simplified form, assuming that the electrons that leave 
complex III ultimately reduce oxygen. Such a reaction is taken to be a hyperbolic function of 
oxygen concentration and proportional to the concentrations of forms able to donate an 
electron.  
The mechanism of electron transport includes steps where highly active free radicals are formed. 
These radicals are capable of passing their unpaired high-energy electron directly to oxygen, thus 
producing superoxide anion radical and then the whole family of ROS such as OH radical and 
peroxides. The system of equations that constitutes this model is described in [17-19].  
Parameter values for the respiratory chain used here were obtained from experimental studies 
[17] of normal mitochondrial function. The model calculates the levels of free radicals of the 
electron carriers constituting the respiratory chain (such as semiquinone radical). These radicals, 
normally formed in the process of electron transport, are responsible for ROS production. These 
levels are presented here as indicators of ROS production rate.  
Overall, the mitochondrial ROS generation model produces two distinct patterns of response to 
P67 at maximum exercise, as displayed in Figure 1. One pattern (HR) reflects above normal high 
ROS generation and the other (LR) reflects little or normal ROS generation. Briefly, the figure 
shows the rate of mitochondrial ROS production expressed as concentration of semiquinone 
radicals (nmol/mg) at Qo site (ubiquinone binding site to complex III at the outer side of the 
inner mitochondrial membrane) of mitochondrial complex III (y-axis) against time (x-axis) for four 
different values of P67 , indicated in Figure 1.  
Note that here, P67  is expressed not as absolute values but as multiples of mitochondrial P50 
(in this case from 0.2 ∗ P to 10.0 ∗ P). For pattern LR, there is essentially no change in ROS 
generation, and this corresponds to the two P67  values exceeding the P in Figure 1. Pattern 
HR is seen in the two examples where P67  is less than P, and here a large, almost 10-fold 
increase in ROS generation occurs. In fact, the switch occurs abruptly when P67  ~ 2 3⁄ ∗ P. 
The high sensitivity of mitochondrial ROS production to restrictions of oxygen transport, and 
thus to low P67 , is a consequence of multistationarity, the mechanisms of which are considered 
in detail in previous publications [17, 18]. Finally, the increase in ROS generation persists after 
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cessation of exercise, and the lower the P67 , the longer the persistence time, also shown in 
Figure 1.  
The non-linear bi-stability inherent to mitochondrial ROS prediction model [17-19] accounts for 
the abrupt change of mitochondrial ROS production rate with a change of external (with respect 
to the respiratory chain) conditions. In principle such a change can be irreversible (in accordance 
with the phenomenon of bistability investigated in [17-19]), but in the considered case it reverses 
with a delay. The delay results from slow oxidation of ubiquinol to ubiquinone, which is necessary 
to activate the Q-cycle in respiratory complex III. The use of P67  normalized to P here reflects 
the fact that while the model predicts different ROS generation rates at different P67  values for 
a given mitochondrial respiration curve of any particular P, when P67  is the same fraction of 
P, ROS generation is the same even if absolute P67  and P are different. For example, if 
P67 = 0.1 and P = 0.2, ROS generation would be the same as that computed when P67 =
0.2 and P = 0.4, because in both cases, P67  P⁄  is the same (= 0.5). This is illustrated in 
Figure 2, panels 1 and 2. In Panel 1, two mitochondrial respiration curves are drawn with the 
above different absolute P values (but the same V̇68; values). Using the above P67  values, 
V̇ in both cases would be the same at 1 3⁄ ∗ V̇68;, shown by the solid circles. Panel 2 replots 
these data normalizing the x-axis by P for each case, and normalizing the y-axis by V̇68; in each 
case.  
These normalized respiration curves now overlie one another, and the important point is that 
the relative P67  values in the two cases are identical and the relative V̇68; values are also 
identical, as will be ROS generation by the two regions. In a similar fashion, it is important to 
recognize that different muscle tissue regions may have different numbers of mitochondria and 
thus different V̇68; values even if P were uniform across regions. The normalization of V̇ to 
V̇68; is thus necessary in order to compare different regions. For example, if V̇ were the same 
at 0.2 units in two regions (and P were also the same in both regions) but V̇68; were different 
at 0.3 and 0.6 units in these two regions (Figure 2, panel 3), V̇ /V̇68; in the first region would 
be 0.67 but only 0.50 in the second region. When the data are replotted to normalize P67  (x-
axis) to P 0 and V̇  (y-axis) to V̇68; (Figure 2, panel 4), the two solid circles now separate. 
Thus, despite similar absolute V̇ values, and the same P, the second region lies lower on the 
mitochondrial respiration curve than the first region. 
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2.4. Integration of the models  
Recall that the oxygen pathway model consists of five equations, the solutions to which define 
the partial pressures of O2 at each step between the air and the mitochondria as well as the 
mass flow of O2 through the system (V̇max). Key input variables for this model are 
mitochondrial V̇68; and P (along with all of the conductances of the O2 pathway). The key 
output variable for linkage to the metabolic model is V̇max (as a fraction of V̇68;).  Thus, once 
the O2 pathway model has been run for any set of input variables, the metabolic model accepts 
as inputs from the O2 pathway model V̇max, V̇68;, and mitochondrial P, which also then 
defines mitochondrial P from the hyperbolic mitochondrial respiration curve. 
After scaling these variables to harmonize the units between the two models (V̇ is in ml/min 
in the pathway model, but in nanomoles/min/mg mitochondrial protein in the metabolic model) 
the metabolic model is run, simulating mitochondrial respiration, i.e. the electron flow that 
reduces the transported oxygen to H2O. The principal outcome of the metabolic model for the 
present purposes is the rate of generation of ROS at exercise conditions for the given values 
of V̇max, V̇68;, P and P67 . 
3. Results 
The main outcome of this study is allowing a quantitative analysis of how the physiological O2 
transport pathway [10-12] affects mitochondrial ROS generation in muscle [17-19]. Figure 3 
shows how maximal V̇ and mitochondrial P in a homogeneous muscle will fall together with 
altitude, as computed from the O2 pathway model.  
Figure 3 also displays the degree of ROS generation as a function of mitochondrial P computed 
from the mitochondrial respiration model. As explained in [17-19], ROS generation abruptly 
switches from low to high levels when mitochondrial P reaches a critical value of 2 3⁄  of the 
P of the mitochondrial respiration curve – in Figure 3 at about 0.1 mm Hg since P is 0.14 mm 
Hg. In this case, the corresponding altitude is 24,000 ft. above sea level. Thus, open circles 
(altitudes less than 24,000 ft.) reflect a state of low ROS generation, and closed circles (altitudes 
greater than 24,000 ft.) reflect a state of high ROS generation. While Figure 3 shows the outcome 
for a homogeneous muscle, in reality the muscles will not be perfectly homogeneous, just as no 
random group of humans will all have exactly the same height or weight. The important type of 
heterogeneity for O2 transport in muscle is that of the ratio of mitochondrial metabolic capacity 
(V̇68;, reflecting ability to consume O2) to blood flow (Q̇, reflecting O2 availability). Thus, with 
heterogeneity, some muscle regions will have lower than average V̇68; Q̇⁄  ratio, and other will 
have a V̇68; Q̇⁄   ratio greater than average. Data on the extent of heterogeneity in muscle are 
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scarce due to lack of methods for its measurement, but recent, unpublished estimates based on 
near-infrared spectroscopy technology (Vogiatzis et al, J. Applied Physiol, under review) suggest 
that a small amount of heterogeneity does exist. 
When V̇68; Q̇⁄   is high (metabolic capacity high in relation to O2 availability), mitochondrial 
P will be low, and vice versa as shown in Figure 4 (simulated for several altitudes from sea 
level to 30,000 ft.). When expressed as the second moment of the V̇ Q̇⁄   distribution, on a log 
scale, the value is about 0.1. This can be compared to the identically computed and well-
established index of ventilation/perfusion (V̇	/Q̇) inequality in the normal lung of 0.3-0.6 [26], 
which is generally regarded as small. Figure 4 also shows the range of V̇68; Q̇⁄   ratios for a 
muscle with normal heterogeneity (i.e., dispersion of 0.1) as from about 0.15 to about 0.36, 
pointing out the large range of mitochondrial P that this seemingly small amount of 
heterogeneity creates. Thus, muscle regions with a high V̇68; Q̇⁄   ratio become susceptible to 
high ROS generation before those with lower V̇68; Q̇⁄   ratio. With the critical switch from low to 
high ROS production occurring at a P67  of about 0.1 mm Hg, Figure 4 shows that with normal 
heterogeneity, the muscle regions with highest V̇68; Q̇⁄  exhibit high ROS production already at 
17,000 ft. altitude, and that at the summit of Mt. Everest (approx. 29,000 ft.), almost 100% of 
muscle regions will have switched to high ROS production. 
Figure 5A shows the consequences of normal muscle V̇68; Q̇⁄  heterogeneity for the 
development of high ROS production in the format of Figure 3. The important points are: i) that 
due to the presence of high V̇68; Q̇⁄  regions, high ROS generation is seen (in those regions) 
already at 17,000 ft., a much lower altitude than for the homogeneous system (24,000 ft.), and 
ii) that high ROS generation becomes more extensive with further increases in altitude.  Figure 
5B shows the percentage of muscle predicted to have high ROS production over the altitude 
range from sea level to the Everest summit. 
4. Discussion 
The results displayed in Figures 3-5 are specific to the input data used (Tables I and II in the 
supplementary on-line material). While they take advantage of the most complete data set 
available on humans exercising over a range in altitude from sea level to the equivalent of the 
Everest summit, the quantitative outcomes presented in this article would be different if a 
different data set were used. This should be kept in mind when interpreting the results 
presented. In addition, some specific, important data are both scarce in the literature and 
uncertain. The most important of these are the mitochondrial respiration curve characteristics 
(here defined by two parameters, V̇68; and P), and the extent of heterogeneity in the 
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distribution of blood flow to muscle regions with different metabolic capacity. However, while 
the particular results we report depend on the values we took for these functions, the important 
point is that the integrated model approach coupling physiological elements of O2 transport with 
biochemical elements of oxidative phosphorylation stands, no matter what specific data are 
used to run it. A graphical user interface to parameterize and simulate the integrated model is 
freely available at https://sourceforge.net/projects/o2ros. 
4.1. Biological and clinical implications 
It is of interest that our results suggest that ROS generation in exercising normal muscle switches 
to high levels already at 17,000 ft., or about 5,000 m. This is the altitude above which permanent 
human habitation does not occur [27], and also the altitude above which humans experience 
inexorable loss of body mass. It is easy to hypothesize a cause and effect relationship between 
ROS and these findings, given the generally pro-inflammatory effects of high ROS levels, but 
whether this is indeed cause and effect or just coincidence remains to be established. In the 
same vein, the widespread presence of high ROS generation within muscle above 20,000 ft. and 
almost uniform presence above 25,000 ft. coincides with what is popularly termed the “death 
zone” in the mountaineering community – altitudes where fatalities are common. Of course, 
bitter cold, high winds, and hypoxia itself are likely contributors to the high risk of death under 
these conditions, but it is possible that high ROS production may be playing a role, not just in 
muscle but perhaps also in critical organs such as the brain. There is a growing body of literature 
[28-30] suggesting that endogenous ROS at high concentrations are damaging to cells, while at 
lower levels they are involved in activating important signaling pathways, some of which relate 
to adaptation to hypoxia (angiogenesis, for example where the promoter region of the critical 
angiogenic gene VEGF has a binding site for H2O2 [31]. They also act as pro-survival molecules 
regulating kinase-driven pathways [28, 32]. A recent systems analysis of abnormal muscle 
bioenergetics in patients with Chronic Obstructive Pulmonary Disease (COPD) [33] provides 
indirect evidence for a central role of cellular hypoxia in explaining abnormal regulation of key 
metabolic networks regulated by genetic and epigenetic mechanisms. Moreover, there is 
evidence [34-36] of the role of nitroso-redox disequilibrium explaining systemic effects in 
several chronic disorders such as COPD, chronic heart failure and type II diabetes. However, 
current knowledge of mitochondrial dysfunction [37-39] is still incomplete. The centrality of 
oxygen metabolism in organisms leads to the notion that it is also involved in other complex 
chronic diseases at essentially every level of organization [5, 40-42].  
Potential applications of the integrated transport/metabolic model, which has been presented 
here only in terms of healthy humans at altitude, are envisioned in systems medicine with 
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analysis of the potentially greater degree of ROS generation associated with impaired O2 
availability in patients with diseases such as COPD, heart failure, diabetes and peripheral 
vascular disease. With the necessary input data, this could be done for individual patients to 
assess the likelihood of high ROS generation in muscle. In addition, the model may allow the 
prediction of the benefits of exercise programs and pharmacological interventions in these 
patients. Through its predictions, the current analysis may open new avenues in assessment of 
the impact of impaired oxygen exchange on increased mitochondrial ROS generation as well as 
in evaluation of the consequences of oxidative stress on biological functions in different acute 
and chronic diseases [5, 6]. While prediction of ROS generation may be possible, it is clear that 
the current integrated model addresses only the relationships between determinants of cellular 
oxygenation and mitochondrial ROS production. It does not attempt to deal with complexities 
of the redox system such as the body antioxidant resources that undoubtedly will modulate the 
biological activity of ROS generated by exercise within muscle, and which will thus affect 
nitrosative/oxidative cellular damage. Accounting for such elements is well beyond the scope of 
this article. 
5. Conclusions 
The integration of the two deterministic modeling approaches considered in this study allows us 
to establish a quantitative analysis of the relationships between the components of the O2 
pathway [13-15] and mitochondrial ROS generation [17-19]. To this end, the simulations herein 
using data from exercising normal subjects at sea level and altitude have shown that when V̇ is 
low (less than 40% of mitochondrial oxidative capacity) due to impaired O2 transport, extremely 
low P67  values will develop, which in turn may be associated with above normal ROS 
production. This will occur when P67 < 2/3 of mitochondrial P. The current investigation 
may open new avenues for assessing the impact of impaired oxygen transport on increased 
mitochondrial ROS generation as well as for evaluating the consequences of oxidative stress on 
biological functions in both acute and in chronic diseases [5,6]. 
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FIGURES 
 
Figure 1.  Dynamics of ROS production (expressed as SQo produced, normalized to total 
complex III abundance (taken as 0.4 nmol/mg mitochondrial protein)) at four steady state 
concentrations of oxygen (expressed as mitochondrial P relative to P50, the oxygen partial 
pressure at the half-maximal rate of respiration). Before and after exercise, rest is simulated (no 
ATP hydrolysis, proton gradient dissipates only due to membrane leak). Between 2 and 6.6 min, 
exercise is simulated (membrane proton gradient dissipates due to ATP hydrolysis and ATP 
synthase activity). Overall, ROS production falls into two distinct patterns: one (HR, seen when 
P67 P⁄ < 0.67) reflects high ROS generation and the other (LR, when P67 P⁄ > 0.67) 
reflects little or no ROS generation compared to rest. Note post-exercise persistence of high ROS 
generation, especially at the lowest P67  to P ratio. 
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Figure 2.  Importance of normalizing both actual V̇ to mitochondrial V̇68; and actual 
mitochondrial P (P67 ) to mitochondrial P when V̇68; and/or P may vary within or 
between muscles. Panel 1: Example of two muscles (A & B) with the same V̇68; but different P 
that happen to have the same absolute V̇ (closed circles). Although P67  is lower in A than B, 
normalization of both axes (Panel 2) shows that in this case, P67  relative to P is the same, 
and this means that ROS generation will be the same for A and B. Panel 3: Example of two 
muscles (A & B) with the same P but different V̇68; that again happen to have the same 
absolute V̇ (closed circles). P67  is again lower in A than B, but normalization of both axes 
(Panel 4) shows that P67  relative to P is lower in A than B, and this means that ROS generation 
will be high for A and normal for B. 
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Figure 3.  Reduction of maximal V̇ and mitochondrial P in a homogeneous muscle as a 
function of altitude, (solid line, computed from the O2 pathway model) and degree of ROS 
generation as a function of mitochondrial P computed from the mitochondrial respiration 
model. Below 24,000 ft, ROS production is low (open circles), but above 24,000 ft, ROS 
production abruptly increases (closed circles). 
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Figure 4.  Mitochondrial P (P67 ) as a function of regional ratios of metabolic capacity (V̇68;) 
to blood flow (Q̇) at four altitudes. The lower Q̇ (supply) is in relation to V̇68; (demand), the 
lower is P67  at any altitude; also, P67  at any V̇68; Q̇⁄  ratio falls with increasing altitude. 
Vertical dashed lines mark the normal range of V̇68; Q̇⁄ . Both panels show the same data, but 
the lower panel expands the y-axis in its lower range to show when ROS generation is high (i.e., 
when P67 < 0.1 mm Hg). Below 17,000ft, ROS generation remains low, but above this altitude, 
regions of normal muscle with high V̇68; Q̇⁄  ratio generate high ROS levels, until at the Everest 
summit, almost the entire muscle generates high ROS levels. 
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Figure 5.  Effect of altitude on ROS generation when considering typical values for lung and 
muscle heterogeneities. A: Between 0 and 17,000 ft., ROS generation is within the normal range 
throughout the exercising muscle (open circles). Open triangles indicate that between 17,000 
and 22,000 ft., abnormally high levels of ROS are predicted in up to 25% of exercising muscle (in 
regions with highest metabolic capacity in relation to O2 transport). The closed triangle (23,000 
ft.) indicates high ROS in 25 to 50% of muscle. The open square (24,000 ft.) indicates 50-75% of 
muscle has high levels of ROS and filled squares (25,000 - 30,000 ft.) show that 75 - 100% of 
muscle regions express high levels of ROS (see text for more details). B: shows in more detail the 
percentage of exercising muscle that generates abnormally high levels of ROS at each altitude. 
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Abstract  
 
Background - Previously we generated a chronic obstructive pulmonary disease (COPD) specific 
knowledge base (www.copdknowledgebase.eu) from clinical and experimental data, text-mining 
results and public databases. This knowledge base allowed the retrieval of specific molecular 
networks together with integrated clinical and experimental data. Results - The COPDKB has 
now been extended to integrate over 40 public data sources on functional interaction (e.g. signal 
transduction, transcriptional regulation, protein-protein interaction, gene–disease association). In 
addition we integrated COPD-specific expression and co-morbidity networks connecting over 6 
000 genes/proteins with physiological parameters and disease states. Three mathematical models 
describing different aspects of systemic effects of COPD were connected to clinical and 
experimental data. We have completely redesigned the technical architecture of the user interface 
and now provide html and web browser-based access and form-based searches. A network search 
enables the use of interconnecting information and the generation of disease-specific sub-
networks from general knowledge. Integration with the Synergy-COPD Simulation Environment 
enables multi-scale integrated simulation of individual computational models while integration 
with a Clinical Decision Support System allows delivery into clinical practice.  Conclusions - 
The COPD Knowledge Base is the only publicly available knowledge resource dedicated to 
COPD and combining genetic information with molecular, physiological and clinical data as well 
as mathematical modelling. Its integrated analysis functions provide overviews about clinical 
trends and connections while its semantically mapped content enables complex analysis 
approaches. We plan to further extend the COPDKB by offering it as a repository to publish and 
semantically integrate data from relevant clinical trials. The COPDKB is freely available after 
registration at www.copdknowledgebase.eu.  
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Background  
 
We previously reported the public availability of a chronic obstructive pulmonary disease 
(COPD) specific knowledge base [1]. This COPDKB semantically integrated existing COPD 
related knowledge such as genotype - phenotype relations or signal transduction pathways into 
structured networks that were connected with clinical and experimental data. To this end an 
object-oriented knowledge model was generated which contained concepts such as “gene”, 
“disease” or “organ” and their associations such as “causes”, “damages”. We established a general 
human molecular knowledge network of over 3.6 million connections (e.g. gene–disease 
associations, protein–protein interactions) with disease-specific signal transduction (54 pathways) 
and metabolite (122) information manually curated from the literature. Initial search, retrieval and 
R-plugin -based data-mining methods integrated into the COPDKB enabled the retrieval of 
disease- or case-specific sub-networks e.g. lung specific by expert users for data analysis and 
model generation. To this end, a thick Java client provided a wizard based user interface to create 
natural language like queries such as  
“Object to find is a Patient which simultaneously is annotated by Patient diagnostic data which 
has GOLD attribute greater than 2 and is annotated by Patient Anthropometrics which has BMI-
BT attribute less than 18 and never is diagnosed with a NCI Thesaurus entry which is inferred by 
ontology entry which has name like `*cancer*'”, which would retrieve all patients diagnosed with 
COPD severity grade above 2 but no cancer which have low body mass index. In addition graph 
based navigation allowed single step network expansions to e.g. navigate from a group of patients 
to the diseases they are diagnosed with and from there to the genes associated with these diseases. 
However, validation with user groups showed that to enable application by clinical researchers, a 
significant simplification of the user interface was required.  
To extend the applicability of the COPDKB as a central part of a biomedical research platform 
we identified several aims: 
1. Update existing and integrate further COPD-specific knowledge and semantically map it 
to clinical, physiological and molecular data of COPD patients to generate a full 
repository of COPD-associated features. 
2. Extend the capability of knowledge representation to include non-SBML-based 
mathematical models and integrate COPD-specific computational models. Semantically 
connect models of different types (e.g. ODE, probabilistic) with each other as well as 
existing relevant data.  
3. Generate an intuitive browser-based user interface for clinical and biomedical 
researchers. 
4. Connect the aggregated COPD-specific knowledge to a clinical decision support system 
(CDSS), which provides translation into clinical practice. 
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Methods 
 
The requirement specification used elicitation methods such as user observations, focus groups, 
interviews and workshops to establish the use cases and workflows, which were refined based on 
a prototyping approach applying agile development methods. The architecture design approach 
followed the ISO/IEC 42010:2007 standard. Implementation of the user interface framework is 
based on the open source Foswiki framework (www.foswiki.org) for which a plugin was 
developed to connect the BioXM™ Knowledge Management Environment. While details of the 
technical architecture of BioXM have been reported elsewhere [2] we briefly summarise it here 
to aid understanding. As depicted in Figure 2 BioXM is implemented as a platform-independent 
Java client–server application with modular architecture and a relational database management 
system backend. The Foswiki plugin calls a dedicated servlet deployed in an Apache Tomcat 
servlet container. The servlet connects to different BioXM application server  programming 
interfaces (APIs) to execute searches and retrieve pre-defined reports through the wiki plugin into 
an html user interface which is accessible by any modern web-browser. A BioXM SOAP web 
service is used to interoperate with external applications such as the Clinical Decision Support 
System (CDSS) and Simulation Environment (SE). Data analyses methods are based on R scripts, 
which the BioXM R-plugin calls and presents the results directly in the user interface. Based on 
this plugin, content displayed in the browser can be dynamically generated from the knowledge 
base repository. The resulting user interface was iteratively validated and refined by focus groups 
of biomedical researchers within the Synergy-COPD projects as well as biohealth research 
students during two subsequent summer schools of the Erasmus Mundus BioHealth Computing 
program.  
Data integration and semantic mapping was performed as described previously [1]. Briefly 
summarized, semantic mapping templates are generated manually between the conceptual data 
model of individual resources and the disease-specific knowledge model. Integration of data 
updates are subsequently performed automatically.  
Manual curation of disease-specific knowledge was generated by extracting from expert-specified 
publications and the results were enriched by expert panel discussions. 
 
Results  
 
Overview of the knowledge base 
 
The COPDKB now provides interoperability and integration between multiple data sources and 
tools commonly used in biomedical research. It also extends to include new tools such as a multi-
scale Simulation Environment [3] that enables the execution of disease-specific simulations based 
on the integration of multiple sub-models. The COPDKB is based on the concept of “knowledge 
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as network” and bridges multiple sources and scales of knowledge by abstracting commonly used 
concepts to communicate disease-specific knowledge into objects and their relations. Structuring 
explicit and implicit knowledge into these formal concepts enables the use of existing, well-
defined vocabularies (e.g. GO[4], ICD10 [5]) and standards (e.g. SBML[6], HL7[7]) to represent 
molecular, biochemical and clinical processes.  
One of the challenges for the use of computation models in biomedical research is the integration 
of models at different scales as well as the mapping to corresponding clinical, physiological or 
molecular data. We defined standard operating procedures for model documentation and 
developed a realisation for the concept of composite use of orthogonal ontologies [8] to create 
semantic descriptions for models, model parameters and clinical parameters. The concept of 
combinatorial ontology use. Traditionally, ontologies are created with the intention to establish 
well defined, highly detailed concepts that capture the full semantic meaning of complex facts 
such as “positive regulation by symbiont of defense-related host calcium-dependent protein 
kinase pathway (GO:0052102)”. In this way such a fact can be expressed by assigning a single 
ontological term. However, due to the complexity and expressivity of descriptions for biomedical 
functions and processes especially in physiology often no single ontological concept will fully 
describe the semantic meaning. Therefore a combinatorial description which combines multiple 
concepts has to be created semi-automatically e.g. by matching a free text description such as 
“partial arterial blood pressure” to terms in existing ontologies and then selecting the appropriate 
concepts from several, ideally orthogonal i.e. non-overlapping, ontologies, to generate an overall 
complete representation such as “MESH:D010313 Partial Pressure; PubChem:977 Oxygen; 
FMA:83066 Portion of arterial blood”. Our realisation of this concept included standards for the 
definition of spatio-temporal compartments to allow ontology-based model–model and model–
data connection. As a rule concepts should be selected from within a single ontology but if this 
does not create a full semantic description concepts from different ontologies can be combined. 
New inference methods are required to make use of such combinatorial descriptions and we 
decided to implement a network similarity search approach, which treats individual descriptors 
as objects in a network and uses within-ontology as well as between-ontology relations to infer 
object equivalence. Specifically, our algorithm treats the collection of descriptors as a specific 
network (semantic_descriptorA) and searches all other existing descriptor collections 
(semantic_descriptorX to semantic_descriptorY) for “similar” networks. A semantic_descriptor 
is more similar to the input the more a) shared nodes (ontology entries); b) identical edges 
(connections between two ontology entries); c) similar nodes (ontology entries connected to the 
identical node by intra- and inter-ontology relationship, i.e., ontological inference) and d) similar 
edges (alternative edge classes connecting identical or similar nodes) are found. A similarity score 
is calculated by summing individual node/edge scores multiplied by the coverage, i.e., total score 
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= Sum(individual scores) * coverage. Individual scores are defined as “1” for identical matches 
and scores for similar nodes/edges are derived by dividing 1 by the number of required steps to 
reach the “similar” object, i.e., a distance-based measure with diminishing contribution. The 
coverage is calculated as a fraction of objects in the input semantic_descriptor actually recovered 
in the search targets.   
 It is therefore possible to deduce, for example, a 98% similarity between the above described 
model parameter and a clinical parameter described as “NCI: C25378 Partial; NCI: C25195 
Pressure; PubChem:977 Oxygen; FMA:45623 Systemic arterial system” (see Figure 1). The 
proposed mappings are verified manually and, if found true, are fixed, enabling the 
parameterisation of computational models based on personalised data, the integrative simulation 
of multi-scale models and the subsequent validation of model predictions against individual 
clinical data. 
In addition to the semantic description of different types of knowledge and data, we therefore 
generated a technical integration between the three compounds required for integrative simulation 
and clinical decision support, the COPDKB, the Simulation Environment (SE, [3]) and Clinical 
Decision Support System (CDSS). We generated an architecture meta-model consisting of the 
following concepts: software components, graphical user interface (GUI), application 
programming interface (API), data types and information flow. Figure 3 shows an integrative 
UML-type diagram of the organisational, infrastructural and informational architecture views 
depicting the involved software components, their APIs and the information flows between them.   
The user interaction was designed within the individual software applications to optimise the use-
case and user-group-dependent issues. Therefore the COPDKB provides the primary access point 
to integrate, curate, search and retrieve COPD-related knowledge; the SE interface is designed to 
enable the explorative execution and personalisation of integrated, COPD-related computational 
models; and the CDSS ideally becomes unobtrusively integrated into the user interfaces of 
existing clinical information and management systems to extend the functionality of accepted 
clinical practice user interfaces to provide disease-specific, individualised support. 
 
Resources included 
 
We extended the disease-specific structured knowledge network significantly with several new 
resources (see Table 1 - Resources integrated into the COPDKB for an overview). Criteria for 
inclusion of new resources were the major aims of the Synergy-COPD project: a) to analyse 
systemic, especially skeletal muscle related mechanisms involved in COPD b) to analyse co-
morbidity related COPD heterogeneity and corresponding molecular mechanisms and finally c) 
to aid the generation of clinical decision support for diagnosis and therapy. To this end we applied 
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literature mining, integration of existing structured databases, clinical studies and ontologies as 
follows:  
1) Additional COPD-associated knowledge was curated from the literature. Within the 
Synergy-COPD  project a main focus was on the understanding for epigenetic regulation 
of muscle phenotypes and development [9] as well as disease co-morbidities derived from 
OMIM gene–disease associations [10] and patient records [11]. 
2) The general knowledge on human regulatory processes was extended by integration of 
miRNA regulation information from miRBase [12] and transcriptional regulation 
information from ITFP [13] . 
3) Regarding clinical COPD data, we integrated a second major study on COPD, PAC-
COPD [14], which focuses on the phenotypic heterogeneity and the extent to which this 
heterogeneity is related to clinical development of COPD.  
4) We extended the range of ontologies integrated into the COPDKB to improve the 
coverage of medical terms, diagnosis and processes. To this end we integrated the 
Medical Subject Headings (MeSH, [15]), the International Classification of Diseases with 
Clinical Modifications, Ninth and Tenth Revision (ICD9-CM, ICD-10-CM) [16] and 
SNOMED [17]. We used the UMLS Metathesaurus [18] to derive mappings between the 
different medical vocabularies and managed to relate over 150 000 concepts. These 
mappings allowed us to integrate a number of different gene–disease association 
resources which had used different disease vocabularies e.g. OMIM or ICD9. 
5) Finally the COPDKB was extended significantly by results derived from the Synergy-
COPD project. 
We updated the expression-based association network derived from the BioBridge clinical study 
[19] with a new version now integrating gene expression data with physiological attributes such 
as VO2max, protein modifications and metabolite measurements providing a COPD-training-
specific network. A further three gene-expression-based association networks specific to 
angiogenesis in young and elderly adults as well as a mouse model on inactivity effects on muscle 
were made available (personal communication FF). 
In addition to the general co-morbidity network mentioned above, two COPD-specific co-
morbidity networks were generated within the project based on US Medicare and Swedish health 
system patient records totalling 13 million patients over 3 years [11] and 5 million patients over 
9 years (personal communication DGC), respectively . To normalise health-system-specific 
differences in disease coding, a disease grouping was developed by clinical experts and integrated 
into the COPDKB. Similar to the disease grouping, we needed to bridge and unify signal 
transduction pathway, transcriptional regulation and metabolism information integrated from 
databases such as KEGG [20] and Reactome [21] as well as from COPD-specific literature mining 
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efforts reported earlier [1]. To this end we generated a Jaccards index-based clustering based on 
the overlap of pathway participants. At a conservative cut off of 0% FDR, this resulted in 13 
groups summarising 421 individual pathways (out of 1367 total). Finally, we integrated 
computational models describing different cells, tissues, organs and physiological processes 
involved in COPD and its systemic effects. Three of these form the core of a COPD disease model, 
specifically a lung air and blood flow model [22] an oxygen transport model [23–25] and a muscle 
cell bioenergetics and ROS production model [26, 27].  
Overall the COPDKB now provides access to almost 850 000 nodes, from genes, proteins and 
metabolites to cells, tissues and organs. 9.5 million associations between these nodes can be mined 
to derive COPD-specific hypotheses and data. 
 
Tools for mining 
 
The simplest way to work with the updated COPDKB is by accessing its new, HyperText Markup 
Language (HTML) and browser-based user interface (see supplemental file S1 for a detailed 
description and screenshots). It provides individual sections for disease-specific public 
knowledge, analysis results, mathematical and network models, as well as clinical data. 
The browsing functions in each of these sections allow users to navigate through specific sub-
sections e.g. the list of all COPD-associated genes or pathways.  
All integrated information can be exported and can be filtered by keyword or numerical value 
using the column selector (e.g. “gene function: DNA binding” or “expression value:  >1 AND < 
100”). Cross-navigation between semantically mapped or associated data types is possible by 
following the “Change type” buttons, for example, to jump from a list of genes to the diseases 
associated with them. The “Data matrix” button allows users to show actual data associated to 
any displayed entity (if the user has access to those data, see above). On such a data matrix the 
“Statistics” button allows access to a simple box-plot overview statistic (mean, STDEV, min, 
max, quartiles) as well as t-test-based comparison of two groups (e.g. FEV1 for high/low BMI 
COPD patients).  
In addition to the simple browse and filter access, we implemented a set of form-based searches, 
which allow more direct access to information and are continuously expanded based on user 
feedback. Currently the search form for patient selection is based on all clinical parameters such 
as BMI or dyspnoea Borg scale, allowing minimum and maximum threshold values to be set 
(Figure 4). Other search forms allow molecular data (e.g. metabolite or protein measurements) 
to be retrieved. 
Two interactive data-mining methods, the network search and network ranking, are currently 
available only from the Java-based expert user interface. These expert-generated results are then 
made available in the standard user interface in the same way as other data. The network search 
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is a variant of the breadth-first-search [28], a graph search algorithm that begins at the root node 
and explores all the neighbouring nodes, which is iteratively repeated for each neighbour until a 
target node is reached. Within the COPDKB the path between nodes (the “associations”) receives 
user-defined penalty scores and only the alternative with the lowest score or all alternatives below 
a certain threshold are retained. Different association types can carry different penalty scores. For 
example, a “high quality” protein–protein interaction (PPI) derived from co-immunoprecipitation 
might carry a penalty score of 1 while a “low quality” PPI detected by two-hybrid experiments 
might have a score of 3. Based on the overall penalty score, shorter and more “high quality” paths 
are preferred. The network ranking method developed within Synergy-COPD takes the result of 
a network search and assigns additional quality values to each of the nodes; these quality values 
can represent complex information such as “number of associated diseases” or “variability in 
muscle expression”, the later derived from the analysis of over 4000 muscle-specific expression 
data sets available in GEO [29]. 
Finally the “network similarity” search is available directly from the standard COPDKB user 
interface. It compares different networks, e.g. signal transduction pathways or semantic 
descriptors of model parameters, based on the occurrence of identical or “similar” nodes and 
associations. In this context similarity is defined as proximity within an ontology. Based on this 
search method, a list of clinical and model parameters, for example, can be ranked according to 
their semantic similarity. 
 
Major uses in Synergy-COPD  
 
So far the major use for the COPDKB has been as the central collaboration and biomedical 
research platform within the Synergy-COPD project. As Systems Medicine is an inherently 
interdisciplinary process, it is extremely important to enable the generation of a common language 
between experts from different disciplines. The COPDKB has been used to map between 
knowledge and data from clinical researchers, computer scientists and mathematicians using the 
semantic description concept and the network similarity search.  Clinical parameters from two 
different clinical studies have been unified and integrated with three computational models and 
eight association networks. While the COPDKB currently provides only simple analysis features 
it has been extensively used to support complex analysis workflows. Integrative network 
association analysis on combined clinical and molecular (expression, metabolic, protein) data was 
enabled by the corresponding data mapping and integration in the COPDKB [19]. The connection 
between data analysis results and the existing computational models was derived from network 
searches which took the highly ranked genes/proteins/metabolites/clinical parameters from the 
data analysis and searched for connecting paths to the described model parameters based on, in 
case of the bioenergetics model [26, 27], mappings to reference genes/proteins/metabolites. 
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Another important type of information provided by the COPDKB were the multiple mapped and 
integrated gene–disease and gene–gene associations. These were mainly used to provide 
molecular connections and mechanisms between different diseases derived, for example, from 
co-morbidity analysis. As described separately, the COPDKB also forms the knowledge 
backbone for the Simulation Environment. It provides the mappings between different models 
that are required by the SE for integrative multi-scale model execution and it subsequently holds 
the simulation results and maps them back to corresponding clinical data for validation. The final 
major use case for the COPDKB is to act as a fact repository for the Clinical Decision Support 
System (CDSS). The COPDKB provides co-morbidity and drug–drug interaction information to 
the CDSS, which subsequently generates alerts on possible disease co-occurrences or adverse 
drug interactions. 
A final important use case turned out to be using the COPDKB as an educational tool to introduce 
non-clinicians to the issues and challenges of COPD-related Systems Medicine. Within the 
Erasmus Mundus BioHealth Computing program, the COPDKB was the initial access point for 
all students to learn about the different aspects of Systems Medicine, from clinical question to 
available knowledge and data, to analysis methods and predictive mathematical models. The 
feedback provided by these focus groups in turn greatly helped to improve the COPDKB user 
interface and shape further requirements. 
 
Discussion  
 
Within biomedical research, we increasingly rely on computational support to keep track of our 
understanding of complex systems such as ecosystems or the human body and its malfunctions. 
So far, within Systems Medicine only a few examples of computational disease knowledge 
resources are available (e.g. [30]) and the COPDKB is to our knowledge the only such resource 
regarding COPD. Moreover, by integrating the COPDKB tightly with a Simulation Environment, 
it extends from a dynamic, but still lexicon-type reference resource, into a truly predictive and 
individual tool. Due to the integration with a Clinical Decision Support System, it is able to deliver 
these individualised predictions directly into clinical practice. 
However, several caveats remain. Although many of the available relevant structured public 
knowledge resources have been integrated, the majority of disease knowledge still remains hidden 
in the literature. Text-mining methods and manual curation provide some inroads into this wealth, 
but are far from sufficient to generate a truly complete picture of our current knowledge. Another 
limitation is the quality and context specificity of the integrated knowledge. Many resources do 
not extract these measures and therefore they remain hidden in the original literature. Detailed 
knowledge structuring efforts, such as developing a mathematical model of a certain process, still 
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require major manual literature-review efforts; the COPDKB only provides a rough framework 
and an indication where to start and which pathways to follow. 
Regarding a full biomedical research platform, the COPDKB currently still lacks accessibility of 
the integrated data-analysis and data-mining methods for non-expert users. The majority of 
available knowledge is on the molecular level and only a small part of it is specific to COPD. 
 
Conclusions  
 
The COPDKB provides a step in our development of a biomedical research platform for System 
Medicine as well as the most comprehensive COPD-specific knowledge base. The COPDKB 
proved a valuable tool for the analysis and computational modelling of COPD although several 
gaps and weaknesses still remain, some inherent to the platform itself, some generic from the way 
we still communicate knowledge. Future developments will focus on three aspects: improving the 
quality of the disease-specific knowledge, extending the integrated COPD-related clinical data 
sources and bringing the validated data analysis workflows into the reach of non-
bioinformaticians. 
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Figures 
 
Figure 1 - Semantic network similarity 
“Equivalent” meaning of different parameters is determined by the overlap of their corresponding 
semantic descriptors, taking into account transitive relations within and between ontologies.  
 
 
 
 
 
 
Figure 2 - BioXM technical structure 
The modular BioXM architecture decouples tasks such as authorisation and access control from 
data management, search and reporting. The dynamic semantic knowledge model defines which 
objects and associations can be represented and analysed. Selecting from multiple “App” 
functions a highly specific browser-based user interface can be generated within the Foswiki open 
source framework. 
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Figure 3 - Software architecture 
Integrative UML-like diagram representing the organisational, infrastructural and informational 
view of the software architecture. All modules communicate based on WebServices. The 
COPDKB provides information of type model, model parameters, parameter values (summarised 
as “simulation knowledge”) and experimental data to the SE. The SE feeds back simulation 
results. With the CDSS the COPDKB exchanges requests for information on knowledge about 
co-morbidities and drug-interactions and provides corresponding search results.  COPDKB = 
COPD Knowledge Base, SE = Simulation Environment, CDSS = Clinical Decision Support 
System, API = Application Programming Interface.  
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Figure 4 - Search form 
Search forms provide pre-defined selections of parameters for which thresholds can be set to 
retrieve data. Here the body mass index was selected to retrieve patients with corresponding 
values.  
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Tables 
 
Table 1 - Resources integrated into the COPDKB 
Data sources added since the first release of the COPDKB 
Resource Information type Number of nodes 
Number of 
associations 
BioBridge omics 
network 2012 
BioBridge 8w training extended by 
protein and metabolite measurements 4878 11448 
Co-morbidity 
network 
Co-morbidity network from OMIM 
gene–disease associations as well as  
Medicare and Swedish health system 
patient data 
8 435 3 973 126 
COPD literature 
mining 
GWAS and epigenetic gene– disease 
associations 18 20 
Disease grouping Expert-based manual grouping of 
diseases 
493 
diseases 27 groups 
Human 
angiogenesis 
young, old 
Public, angiogenesis-related expression 
data 3691 3782 
ICD 9 International classification of disease, ninth revision 13 222  
ICD 10 International classification of disease, tenth revision 12 416  
ITFP Transcription factors and targets 
2 143 TF, 
6 710 
targets 
74 907 
MeSH Medical subject headings 24 767  
miRbase micro RNA 
2024 
human 
miRNA 
 
miRTarBase microRNA targets 
12 194 
human 
targets 
38 311 
Mouse inactivity-
induced muscle 
wasting 
Public mouse, inactivity-induced muscle 
wasting data gene expression GSE25908,  15 287 154 597 
PAC-COPD Clinical study 
342 
patients, 
260 
clinical 
attributes 
 
Pathway network 
Jaccard index based clustering of 
pathways from KEGG, Reactome and the  
BioBridge COPD text mining 
1138 
pathways 
1815 
associations 
SNOMED-CT Systematized Nomenclature of Medicine 
— Clinical Terms 296 519  
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ABSTRACT 
 
Background – Integrated Care Services (ICS) supported by Information and Communication 
Technologies (ICT) enhance health outcomes in a cost-effective manner, but deployment of ICS 
in areas involving heterogeneous healthcare providers is still a challenge. Change management 
and ICT strategies constitute two pivotal factors modulating success of deployment of ICS. The 
current manuscript reports on the ICT developments carried out to support the deployment of four 
ICS as part of the EU project NEXES. 
Results – The Linkcare® platform facilitated patient-centered management through shared-care 
plans across healthcare tiers. It provided collaborative tools underpinning organizational 
interoperability among actors: professionals and patients/caregivers. Moreover, it offered 
integration with provider-specific electronic health records via interoperability middlewares or 
using regional health information exchange tools. NEXES demonstrated effectiveness, 
complementariness and high potential for cost-containment in the four ICS assessed: Wellness 
and Rehabilitation (n= 282); Enhanced Care (n=1,037); Home Hospitalization and Early 
Discharge (n=2,404); and, Support to remote diagnosis (n=8,047). 
Conclusions - Linkcare® covered the technological requirements of the project providing key 
ICT functionalities to support ICS for chronic conditions. Moreover, the flexibility of the ICT 
platform ensures readiness to support various regional deployment strategies.    
 
Key words:  Chronic care, Clinical Decision Support Systems, Care coordination, eHealth, 
Integrated Health Care Systems 
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1. Background 
Health systems worldwide are facing a profound evolution driven by three major forces that are 
converging in terms of their impact on health information systems. Firstly, the epidemics of non-
communicable diseases [1-3] is prompting both conceptual and organizational changes in the way 
we approach delivery of care for chronic patients. A second vector of change is the need to ensure 
financial sustainability of healthcare systems by generating efficiencies that ideally should lead 
to containment of overall healthcare costs without precluding the necessary innovations [1]. Last, 
but not least, Systems Medicine [4] is proposing an innovative approach to our understanding of 
disease mechanisms that is contributing to build-up personalized medicine [5] with important 
implications on future strategies for patient management.   
A commonality of these three driving forces is the need for efficient and intensive use of 
Information and Communication Technologies (ICT) to support novel Integrated Care Services 
(ICSs) for chronic patients [6]. However, conventional Health Information Systems (HIS) only 
very rarely incorporate the required process logic to support ICSs management [7]. Conventional 
care relies on the management of clinical episodes with a disease-oriented approach, whereas in 
ICSs continuity of care with a patient-centered approach are key principles. Most importantly, 
integrated care requires organizational interoperability among healthcare providers and with 
social support.  
We acknowledge that examples of successfully addressing the technological requirements 
associated with the deployment of ICSs within a given health information network do exist [8, 9]. 
However, this issue remains a major challenge in those healthcare sectors with heterogeneous 
providers each one using proprietary HISs. Moreover, there is a need for new paradigms bridging 
traditional Electronic Heath Records (EHR) and informal care through patient’s personal health 
records. 
The development of the Integrated Care Shared Knowledge platform (Linkcare®) reported here 
was part of the NEXES project [10]. NEXES aimed at assessing the deployment of four different 
ICSs covering the entire spectrum of severity of chronic patients. The project was conducted in 
three European sites: Barcelona (Catalonia); Trondheim (Norway) and Athens (Greece). The 
hypothesis behind the study was that a comprehensive ICT platform fulfilling the requirements 
of ICS plays a significant role for the successful deployment of the novel services.  
Each of the sequential building blocks of a given ICS (i.e. case identification, case evaluation, 
work plan definition, follow-up and event handling, and discharge) typically involves the 
participation of a limited number of actors. If properly designed, each of these blocks should 
render outcomes that are relevant for execution of the next phase. Identification of  tasks and 
allocation of them to the different actors was described using the BPMN (Business Process 
Modeling Notation) [11] formalism. Despite the descriptive part of the BPMN for each ICS can 
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be generalized to all settings, the design needs to be contextualized to optimize performance. The 
BPMN formalism was used to create the process logic of the ICS and to formalize the Linkcare® 
core functional requirements. This is to be complemented by other non-functional requirements, 
including interoperability with existing proprietary Health Information Systems (HIS) and 
privacy and security controls. 
The current study reports on the technological developments carried out to support the process 
logic of ICS in a care coordination scenario. The manuscript describes: (i) the processes followed 
to develop the logics of the clinical processes and the associated ICT support; and, (ii) a summary 
of the ICS outcomes endorsing the adequacy of the technological setting. Further developments 
of the Linkcare® platform were carried out beyond the project, as part of the process of regional 
deployment in Catalonia. The characteristics of ICS and its practical implementation and 
assessment in NEXES have been extensively reported elsewhere [12]. 
 
2. Implementation 
We adopted Enterprise Application Integration (EAI) software architectural principles [13] since 
they provide a common basic set of ICT solutions for integration at site level with potential for 
scalability. This option allowed integration with external legacy systems using interoperability 
middlewares for extending the core module with third-party functionalities. Overall, Linkcare® 
acts as a common facade, on top of existing Health Information Exchange (HIE) systems, with 
functionalities that facilitate organizational interoperability between professionals participating 
in ICSs management and execution. The European legislation on health data transfer and security 
[14-17], as well as the specifics of its real application at site level were analyzed and compared 
with particular emphasis on the impact of ICSs deployment. Moreover, the international 
regulations on medical devices [18-20] were also considered in the design of Linkcare®. Crucial 
to the success in adopting the proposed ICT solution was the goodness of fit between technology 
and work practices of the end users [21]. To this end, at different time points in the process of 
implementing the current Linkcare® platform, different evaluation methods and tools were 
applied with specific purposes following the iterative approach described by Catwell et al. [21]. 
Since early development phases, we introduced specific tools of formative evaluation to verify 
assumptions, generate understanding and reveal incidences in order to minimize future problems, 
namely: misunderstanding of specifications, rejections by end-users, etc. To this end, the Method 
for the ASsessment of Telemedicine applications (MAST) was used for iteratively evaluating the 
technological developments. Moreover, when the Linkcare® platform was operational, we 
incorporated tools of summative evaluation to assess outputs. 
Linkcare® acts as a common interface exposing only the relevant information and interfaces of 
the underlying applications to the end-user. To this end, the system uses a component-based three-
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tier architecture as depicted in Figure 1. The three-tier architecture consists of the following 
presentation, logic and data tiers.  
Presentation tier 
The presentation tier is composed of (i) a set of separate web portals for ICS management and 
execution (professionals portal), for team management, for call center operators (automatic call 
identification and call event processing), for patient self-management (self-explorations, 
educational material and event posting), the ICS Editor, and for system maintenance; and (ii) an 
Android application [22] to allow self-explorations and remote measurements using wireless 
medical device. 
Logic tier 
The logic tier dispatches through a SOAP web service bus all user-interface transaction requests. 
This allows easily embedding Linkcare® into existing corporate systems (in-place HIE if 
available) and provide a mean to facilitate privacy-preserving health data mining. All web service 
requests are properly recorded for data access tracking purposes and audit. The SOAP web 
services are divided into five main categories (see Multimedia Appendix 2 for a comprehensive 
technical specification of the currently available web services). System Services are designed to 
provide system parameters, such as language lists, multilingual descriptions, roles, source 
references, etc. Session services are used for session persistence acknowledgement. Center 
services provide organization information of a particular center, such as center-associated users, 
users and user’s roles. Centers can be associated to other centers, and grant them access or 
administrative relations. So users who belong to different organizations can access the shared 
clinical data. Library services allow access to the resource library. The main library resources are 
the ICS templates, the work plan templates and the ICS available tasks. Finally, Clinical Data 
Bank Services anonymously store and exchange clinical information of cases. Linkcare® 
maintains a list of case identifiers that point to one or more health care information systems to 
retrieve the personal data. However, the personal data itself is not stored in Linkcare®, and each 
user access to such data is retrieved from the related source in real time, passing the user’s 
credentials for that particular source.  
Data tier 
Finally, the data tier anonymously records all task and event execution information in a local or 
cloud database management system. Interoperability with clinical data is ensured by supporting 
different sets of terminology (i.e. International Classification of Diseases, ICD-9CM; SNOMED) 
and the HL7 2.5/3 standard for exchanging information between medical applications. A detail 
description of the system software and hardware requirements is provided in Multimedia 
Appendix 1. 
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3. Results and discussion  
The core technological output of NEXES [10] was an open source Integrated Care Shared 
Knowledge platform (Linkcare®) released under a Creative Commons license, based on (i) 
patient-centered management via agreed ICSs, and (ii) technical support for coordination of 
healthcare professionals, considering ICSs as the archetypal coordination model. To this end, 
basic functionalities of the  Linkcare® platform (Figure 2) include: ICSs management with web-
based and user-friendly portals for healthcare professionals (Figure 3, upper panel) and patients 
(Figure 3, lower panel), integration with provider-specific EHR, interoperability with remote 
monitoring devices (by means of the Linkcare Mobility Android App [22]), integration with 
clinical decision support systems, incorporation of support center functionalities and delivery of 
educational resources. It is of note that integration at site level should be provided by the local 
systems integrator using, if available, local or regional Health Information Exchange. In the 
following sections, we take a generic ICS to describe the user roles, how an already existing 
generic ICS is managed and executed and what are the functionalities and software architecture 
principles Linkcare®. 
 
3.1. Linkcare® user roles 
Linkcare® considers a miscellaneous set of roles belonging to the following three main categories: 
i) Patient/Caregiver - this category identifies the primary recipient of the services. Within a given 
ICS tasks can be assigned to both patients and/or caregivers; ii) Health & social care professional 
- this role category encompasses the set of professionals that are members of the teamwork for a 
given patient and ICS. It is of note the importance of the Case Manager role as the professional 
holding responsibility, for a given ICS and patient, on team performance and program execution; 
and iii) Assistant roles - this category includes clerical workers and call center operators having 
access to a reduced set of assistant-specific user and patient data views. Additionally, ICT related 
roles (system administrator, operator manager, etc.) are also supported by the Linkcare® platform. 
 
3.2. Incorporating a new ICS template: The ICS editor  
The internal relational entities (depicted in Figure 4) and software architecture of Linkcare® 
support the process control logic of ICSs depicted in Figure 5, which core elements can be 
customized with the ICS editor, a suite of tools to graphically manage the following main four 
ICS components: i) Linkcare® users - this interface allows to register new professionals, and to 
manage healthcare teams already participating in any ICS supported by the Linkcare® platform. 
Users are required to indicate their ID and contact information, preferred working language, 
username and password and working hours. The user roles during the management and execution 
of the ICS will also be specified at this stage. Most of this information can be extracted from local 
authentication servers; ii) ICS template - ICS templates serve as a reference framework being later 
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customized to patient-specific conditions and the local characteristics of the healthcare provider. 
An ICS template is composed of a set of admission and discharge forms, templates for reporting 
admission, follow-up and discharge reports, as well as a predefined work plan; iii) Electronic 
forms - this interface allows to incorporate new forms (electronic questionnaires and checklists) 
to the library of forms or to manage already existing ones. At edit mode, each question can be 
stated in several languages and formulas can be incorporated into the questionnaire. The library 
of forms allows to share and reuse questionnaires and checklists (see examples in Multimedia 
Appendix 1). Besides electronic forms, Linkcare® also allow professionals to customize report 
templates. Normalization of data collection via electronic forms using standard terminologies, 
and report templates empowers the ability of Linkcare® for privacy-preserving health data mining; 
and iv) ICS tasks - ICS templates have an associated work plan template, which is a set of tasks 
or interventions (e.g. questionnaires, vendor-specific remote monitoring of vital signs, audio and 
video conferences, etc.) scheduled to be executed during a predefined period of time, or always 
available (patient’s optional tasks). Work plan templates can be customized to patient-specific 
needs selecting tasks from the ICS library of available resources.  
 
3.3. ICS management and execution 
Once the agreed ICS is incorporated into the Linkcare® platform, healthcare professionals can 
start the management and execution of the ICS. Depending on their role in the given ICS, 
professionals will have different access and operational rights. 
The general functional workflow for ICS planning and execution, depicted in Figure 5, expands 
the ICS Work plan definition stage, into two functions: Work plan customization and Task 
assignment, allowing to better differentiate between the customization of the work plan template 
to patient-specific conditions and the planned management of both tasks and healthcare 
workforce. The technological implications of these stages and their functional workflow are 
described in detail below. 
3.3.1. Case identification 
This first step allows labeling a new case as eligible for enrolment into the Linkcare® platform, 
still with no selection of a specific ICS, which will be performed by the same or another healthcare 
professional during case evaluation. Patient information stored in external provider-specific EHR 
can be retrieved at this stage to ease case identification. 
3.3.2. Case evaluation 
In this step, professionals gathers information from patients with a twofold aim. Firstly, patient’s 
inclusion into a given ICS template and, secondly, comprehensive assessment of the case to 
facilitate the work plan definition. Patient inclusion is associated to eligibility established through 
well-standardized forms. In addition, healthcare professionals can have access to the history of 
previous disease episodes stored in the corporate EHR and the history of previous and current 
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ICS admissions to support case evaluation, ultimately leading to the next stage for Work plan 
definition or discarding the case if not eligible.   
3.3.3. Work plan definition 
The work plan can be built from scratch or based upon an ICS-specific predefined work plan. As 
mentioned above, we distinguish the following two sub-stages: i) Work plan customization - this 
stage allows the selection of specific tasks to personalize the predefined work plan to patient-
specific conditions and needs. The library of tasks available, designed and evaluated in NEXES 
[10], included: informative documents supporting diagnosis, treatment and ICS management, 
electronic forms, tasks associated to the support center (i.e. phone calls, SMS messaging, 
videoconferencing, etc..) and patient remote monitoring using either electronic questionnaires or 
wireless sensors of vital signs; and ii) Task Assignment - it corresponds to scheduling and 
allocation of tasks to the individual professionals of the team (e.g. healthcare professional, patient, 
social worker, etc.) taking into account the agenda of individual members of the care team. 
Otherwise, ICS optional tasks have a predefined task leader and can be performed anytime. 
3.3.4. Follow-up & events handling 
This stage corresponds to the running and management of a given ICS in a particular patient until 
its termination. In addition, this step encompasses event management. Events are generated by 
the patient (case) or by professionals (issuer agent) and registered to the system by healthcare 
professionals (poster agent) to request a service or advice to another professional or team 
(assigned agent). Events can be also generated because of the findings reported in a task. A 
specific event called Second Opinion allows requesting collaboration with other Linkcare® users. 
During the execution of the ICS work plan, follow-up reports can be generated and delivered to 
be stored in an external EHR. The continuous patient’s assessment during this phase may lead to 
changes in the working plan triggered by unexpected events. 
Patient self-management is a crucial part of ICSs. Accordingly, Linkcare® supports patients’ 
empowerment with a web-based patient gateway, which allows patients access to their optional 
and scheduled tasks, to review their follow-up, to check educational information, to share 
documents of their choice with its case manager and the remote monitoring of patients’ vital signs. 
3.3.5. Discharge 
Once the assigned ICS working plan is completed, the patient can be discharged or re-evaluated 
to be included in a different ICS. The ICS execution can also be terminated by patient’s voluntary 
decision or by a change in the personal or health conditions that would make him/her no longer 
eligible. Ultimately, patient discharge reports are generated and sent to the corresponding EHR. 
 
3.4. System usage and performance 
The current Linkcare® platform successfully supported the deployment of the four ICSs, as 
described in detail elsewhere [12] and in the Multimedia Appendix 3 (Lessons Learnt in the 
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Validation Trials and Supporting Investigations), with full technical integration at site level (i.e. 
integration with the corporate EHR of the Hospital Clinic). Main features of Linkcare® are 
highlighted in Table 1.  
A total of four major ICSs, designed and evaluated in the NEXES project [10], were created, 
managed and executed with the support of Linkcare®: i) Wellness and Rehabilitation (W&R), 
composed of one-year follow-up with ICT support after endurance training aiming at generating 
sustainability of training effects and fostering healthier lifestyles in clinically stable patients 
(entered, n=337, completed, n=154); ii) Enhanced Care (EC) for frail chronic patients targeting 
to reduce hospital admissions (n=1.541 and 1,340); iii) Home Hospitalization and Early Discharge 
(HH/ED) targeting tertiary bed savings and early readmissions avoidance (n=4.534 and 2.404); 
and,  iv) Support to remote diagnosis (Support) for the remote quality assessment of spirometry 
testing (n=8,139 all completed). The four major ICSs were assessed in two European sites: 
Barcelona (ES), 540.000 inhabitants, driven by a tertiary hospital (11.128 patients) and Athens 
(GR), pilot studies conducted by a tertiary hospital (388 patients). During the project lifetime [10], 
in the Barcelona site, the assessment of the four ICSs ran in parallel with significant organizational 
changes promoting transfer of hospital-based specialized care to extramural community care. 
These ICSs should not be envisaged as silos. Instead, their adequate articulation in a given patient 
allows appropriate coverage of the complexities faced in chronic care [12].  Effectiveness, 
complementariness, transferability and cost-containment of the four ICS were proven in 
Barcelona and GR [12]. The project also identified strategies to foster EU deployment of the 
model of care. 
 
3.5. Technological achievements and challenges for large-scale deployment 
The current study describes the characteristics of the modular open-source ICT platform 
conceived to cover the requirements for deployment of the NEXES’ field studies [10]. The 
platform (Linkcare®) has been operational during the project lifetime in one of Barcelona’s Health 
Care Districts accounting for 540.000 inhabitants, showing potential for further deployment at 
regional level. Overall, Linkcare® incorporates integrated care clinical process logics allowing 
patient-centered management with high potential for both patient-specific and provider-specific 
customization. Ultimately, only the core of the platform encoding ICS-specific process logic is 
required for deployment. Either the presentation or the data tiers can be accommodated to site-
specific requirements. 
Linkcare® has adopted a Health Information Sharing (HI-Sharing) approach that allows sharing 
data over complex processes without having to make changes to the corporate HIS or EHR data 
structures. In this sense, all patient information gathered and managed by the Linkcare® platform 
is reused, if possible, from existing EHRs. Otherwise, new data entered to the system (e.g. patient 
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remote monitoring measurements, patient answers to questionnaires, etc.) can be then delivered 
to the corresponding EHR. Within this scenario, Linkcare® acts as a common interface for 
electronic health information that is properly integrated based on the agreed ICS workflow.  
Key aspects of Linkcare® have been evolving beyond NEXES and the preparatory strategies for 
regional deployment have been formulated. The open and modular nature of the Linkcare® 
platform should facilitate its extensive deployment following the scheme depicted in Figure 6 
and the implementation strategy developed within NEXES for the transfer from a HIE setting to 
a HI-Sharing in Norway (see Annex I from the Multimedia Appendix 3). As depicted in Figure 
6, the Integrated Care Shared Knowledge platform (Linkcare®) presented here will support the 
execution of complex integrated care processes while keeping messaging responsibility on 
regional Health Information Exchange (the WIFIS project in Catalonia). Currently supported 
processes have defined a set of reference HL7 messages, which will be extended with the new set 
of messages that will ensure organizational interoperability between the different healthcare tiers 
supporting the execution of the each one of ICSs considered for regional deployment. Moreover, 
patients will access their personalized work plan to perform their tasks throughout the Catalan 
patient gateway (i.e. Personal Health Folder). In addition to the Personal Health Folder, the 
Catalan shared electronic health record (HC3), which currently acts as a common digital 
document repository but will capitalize Health Information Exchange across health sectors, are 
the two key bridging tools for technical interoperability between the different Catalan Health 
Sectors. 
3.6. Technological lessons   
The experience gathered in the other two NEXES sites, Athens and Trondheim, was extremely 
useful to identify those conditions wherein the implementation of Linkcare® may show different 
types of limitations.  
In Norway, NEXES was deployed in the Central Norwegian Region Health Area (CNRHA) as 
part of the preparatory phase of the Coordination Reform [23, 24]. Since the very beginning of 
the project [10], however, it became apparent that the Norwegian legal frame on health data 
transfer precluded the use of the current Linkcare® platform for deployment of the ICSs.  Instead, 
an alternative nationwide platform based on exchange of electronic messaging among providers 
(HIE) was used. During the project lifetime, it has been shown that technological support of ICSs 
based on a pure HIE approach constitutes a clear limitation for the deployment of integrated care 
being a significant explanatory factor of the lack of effectiveness of the interventions on the 
Norwegian site in W&R and EC. 
In Greece, a core initial version of Linkcare® was used to support the NEXES field studies as an 
standalone application because of the lack of a fully operational HIS in place, at least until 2011. 
The project in Athens was developed by qualified and motivated early adopters of ICSs and it 
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provided valuable information for deployment of chronic care in a highly fragmented health 
system.  
 
3.7. Future developments  
Linkcare® can be used for not only patient management, but also it can also have a role as 
knowledge sharing tool across healthcare sectors. Most importantly, it can evolve as a platform 
bridging healthcare sectors with informal care (i.e. life style management or case finding 
programs run by informal careers) [25, 26] through integration of the personal health folder 
already assessed in NEXES, as part of the Wellness and Rehabilitation ICS [27]. Moreover, 
Linkcare® also shows possibilities as a tool bridging formal healthcare with bioscience research 
[28]. All this potential leads to new exciting challenges that will need to be faced to successfully 
pave the way for the development of the future 4P (Predictive, Preventive, Personalized and 
Participatory) medicine for patients with chronic conditions.  
 
4. Conclusions 
The Integrated Care Shared Knowledge platform (Linkcare®) successfully provided technical 
support, considering ICSs as the archetypal coordination model, for the management of the four 
complex ICS assessed in NEXES [12]. Linkcare® builds on top of Health Information Exchange 
to facilitate large-scale deployment of integrated care because it facilitates the transfer of 
complexity from specialized care to the community and to patients’ home.   
 
5. Availability and requirements 
 Project name: Linkcare API 
 Project home page: http://wiki.linkcare.cat 
 Operating system(s): Platform independent 
 Programming language: Any SOAP compliant client 
 Other requirements: SaaS subscription 
 License: CREATIVE COMMONS 
 Any restrictions to use by non-academics: commercial license needed for commercial 
distribution 
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Tables 
 
Table 1. Ten principal features of the Integrated Care Shared Knowledge platform (Linkcare®). 
1. Supports the clinical process logics of Integrated Care Services  
2. Highly customizable to both patient and site characteristics  
3. Technical interoperability with Electronic Health Records across healthcare 
tiers, directly or via in-place Health Information Exchange  
4. The implementation does not require replacement of pre-existing proprietary 
Electronic Health Records 
5. Key technical elements for organizational Interoperability at a health system 
level 
6. Open source 
7. Three-tier architecture 
8. Integration with Clinical Decision Support Systems  
9. Compliant with knowledge management tools 
10. Potential for bridging with informal care and biomedical research  
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Figures 
 
 
Figure 1. Three-tier architecture of the Linkcare® platform. This multitier architecture allows 
separating the presentation or graphical user interface, business or application and data 
management logics, which permits the option of modifying or adding a specific layer, without 
reworking the entire application, in response to changes in requirements or technology.  
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Figure 2. Based on patient-centered ICSs, the Linkcare® platform provides key technical 
elements for organizational interoperability between healthcare professionals from various tiers 
of care and enhances accessibility and proactivity of both patients and caregivers. This is thanks 
to specific functionalities attached to the Linkcare® platform via interoperability middlewares. 
These functionalities facilitate access via the support center and portals. The traditional call center 
functionalities are enriched with novel patient gateways and portals for healthcare professionals. 
Other interesting features are patient empowerment for self-management of his/her condition with 
remote monitoring, integration with site-level Electronic Health Records (EHR) and automated 
clinical decision support. 
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Figure 3. The upper panel shows the Linkcare® web-based user interface for healthcare 
professionals, which provides an overview of the patient information, a calendar view of the 
patient’s work plan status and a set of tools for work plan follow-up and personalization. The 
lower panel shows the home page of the Linkcare® patient gateway used to support the wellness 
and rehabilitation ICS evaluated in the NEXES project. From this home page, patients can access 
to their optional (“ACTIVA’T”) and scheduled (“AGENDA”) interventions, patients can easily 
review their follow-up (“SEGUIMENT”), check educational information (“INFORMACIÓ 
D’INTERÈS”) and finally send patient’s documents of their choice to professionals 
(“COMPARTIR DOCUMENTS”). 
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Figure 4. Linkcare® relational entities that support the creation and edition of ICSs. The Library 
of ICSs contains the set of available ICS templates and the system users potentially having a role 
in ICS management and execution. ICS templates are composed of admission and discharge form 
templates and a customizable work plan, which is used as the reference guide for the scheduling 
of tasks and the generation of follow-up reports. Finally, event handling is provided during the 
execution of the patient-specific work plan. 
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Figure 5. Linkcare® workflow for ICS management and execution. The corresponding ICS 
template is used as a library of resources for the correct customization and execution of the ICS 
workflow. Integration with corporate EHR allows instant access to required patient information 
for case identification and evaluation, avoid data duplicity and preserve the current corporate 
clinical data chain of custody. Follow-up and discharge reports can also be sent to the corporate 
EHR to keep trace of the ICS execution as part of the patient clinical episodes. 
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Figure 6. Interoperability framework for the regional deployment of the current HI-Sharing 
platform (Linkcare® - orange box) in a Catalan Health district and/or sector level. The Catalan 
Region has seven different healthcare sectors depicted in the figure. The sectorial HIE framework 
(i.e. the Catalan WiFIS standard) integrate basic highly standardized processes, namely: medical 
appointments, clinical data exchange, medical referral, etc., among healthcare providers with 
heterogeneous proprietary systems. In this scenario, the deployment of novel ICSs will be 
supported by the HI-Sharing platform (Linkcare®) described in the current study. At regional 
level, the Catalan Shared Electronic Health Record (HC3) currently acts as the common 
repository for health data exchange. However, it could also perform sectorial message routing and 
message delivery control. Finally, citizens can access their health related data via a Personal 
Health Folder (PHF) connected to the HC3. The PHF can also act as the citizen entry point for 
some of the supported processes (e.g. Medical appointments, participation in ICSs, etc.) and 
informal health data sources (e.g. mobile health applications, community medical devices, etc.). 
The NEXES project has shown a high potential of the PHF to support patient’s empowerment for 
self-management and healthier life styles [27]. 
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Abstract 
This article describes a Digital Health Framework (DHF), benefitting from the lessons learnt 
during the three-year life span of the FP7 Synergy-COPD project. The DHF aims to embrace the 
emerging requirements – data and tools – of applying systems medicine into healthcare with a 
three-tier strategy articulating formal healthcare, informal care and biomedical research. 
Accordingly, it has been constructed based on three key building blocks, namely, novel integrated 
care services with the support of information and communication technologies, a personal health 
folder (PHF) and a biomedical research environment (DHF-research). Details on the functional 
requirements and necessary components of the DHF-research are extensively presented. Finally, 
the specifics of the building blocks strategy for deployment of the DHF, as well as the steps 
toward adoption are analyzed. The proposed architectural solutions and implementation steps 
constitute a pivotal strategy to foster and enable 4P medicine (Predictive, Preventive, Personalized 
and Participatory) in practice and should provide a head start to any community and institution 
currently considering to implement a biomedical research platform. 
Key words:  Biomedical Research, Chronic care, Clinical Decision Support Systems, Integrated 
Health Care Systems, Patient Decision Support Systems, Personal Health Folder  
 
1. Background  
The seminal purpose of the systems medicine design [1] conceived for the Synergy-COPD project 
[2] was to generate knowledge on underlying mechanisms explaining heterogeneities observed in 
chronic obstructive pulmonary disease (COPD) patients. The ultimate aim of the project was to 
use such knowledge to refine patient’s stratification, prognosis and treatment response, which 
then should lead to efficient preventive strategies aiming at modulating disease progress while 
reducing the burden of COPD on healthcare.  
It is well accepted that predictive medicine is opening entirely new and fascinating scenarios for 
the interplay between clinical practice and biomedical research. However, at the same time, it is 
generating novel requirements with impact on adoption. Firstly, the need for multilevel 
integration of heterogeneous patient information (Figure 1), namely: socio-economical, life-style, 
behavioral, clinical, physiological, cellular and “omics” data [3] and their use for the design of a 
personalized digital patient from virtual physiological models. Secondly, the need to extend 
current trends on open data from the biomedical community [4] to the clinical  practice and the 
whole society, by engaging citizens and solving privacy and regulatory constraints, Finally, the 
need for highly applicable user-profiled functionalities for data management and knowledge 
generation. Accordingly, innovative and robust Information and Communication Technologies 
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(ICT) will be needed as supporting tools to overcome well-identified current functional 
limitations [5].  
The concept of Digital Health Framework (DHF) (Figure 2) emerged from the Synergy-COPD 
project to foster adoption of predictive medicine. The DHF consists of the articulation of open 
and modular ICT components supporting organizational interoperability, and appropriate 
functionalities, among three main areas, namely: i) informal care, ii) formal care, and, iii) 
biomedical research. Briefly, informal care includes any aspect with impact on health (e.g. life 
style, environmental and behavioral aspects, etc.) occurring in the community, whereas formal 
care refers to any interaction with health professionals at different levels of the healthcare system. 
Biomedical research refers to all research levels from bench to clinical and to public health. In 
our hands, to materialize such an ambitious vision, a building block approach is considered 
necessary. Moreover, the progress from the initial proof-of-concept to pilot implementation and 
to extensive deployment shall be planned following a stepwise strategy. 
The first building-block was the design and initial deployment of an open source Integrated Care 
Shared Knowledge Platform supporting Integrated Care Services (ICS) for chronic patients [6], 
initiated at the EU project NEXES [7]. During the life span of NEXES, a Personal Health Folder 
(PHF) was successfully piloted [8], as a supporting tool to achieve long-term sustainability of 
training-induced effects and promote active life styles in COPD patients. The PHF constitutes the 
second building block currently being implemented in a health district (Barcelona-Esquerra, 
540.000 inhabitants) in Barcelona as a tool to integrate informal and formal care in community-
based ICS for frail chronic patients [9]. Moreover, the Clinical Decision Support Systems 
(CDSS) generated during the Synergy-COPD lifetime (described in the “Clinical Decision 
Support Systems (CDSS) for preventive management of COPD patients” chapter of the current 
monograph) has been integrated into the platform supporting ICS [6]. Consequently, the interplay 
between the first two building blocks (informal and formal care) is operational in a controlled 
deployment scenario and is currently evolving toward maturity. We shall keep in mind, however, 
that active citizens/patients together with a prepared multidisciplinary health workforce will be 
the real key drivers of the transition from current healthcare practice to full deployment of 
predictive medicine for chronic patients.       
The current report focuses on the third building block of the DHF, tackling biomedical research 
(DHF-research). The manuscript analyses architectural design, functionalities and 
implementation strategies of interoperability between healthcare and biomedical research. 
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2. Progress from this paper 
We report on the key elements needed for the design of the DHF-research, showing 
interoperability with the open Integrated Care Shared Knowledge Platform already operational in 
the Barcelona-Esquerra health district. From the methodological standpoint, the manuscript 
performs a systematic description of the DHF-research architecture and functionalities based on 
the lessons learnt in Synergy-COPD indicating the contributions beyond the current state of the 
art. The expected outcome of the manuscript is to generate a proof-of-concept of the DHF-
research component as well as to propose strategies for its assessment and future implementation.   
 
3. The DHF principles: lessons learned from the Synergy-COPD project.  
3.1. Main actors of the DHF   
Table 1 describes the profiles of typical actors in the DHF: biomedical research actors (Clinical 
and Basic scientists), healthcare actors (specialized and primary care), and three patient profiles 
corresponding to three possible COPD status (moderate COPD, complex COPD and COPD with 
comorbid conditions). Furthermore, the three patient profiles represent different levels of 
stratification and personalized therapeutic strategies guided by CDSS. The CDSS is embedded 
into the Integrated Care Shared Knowledge Platform [6] which, in turn, make summary PHF 
information available to the clinician. In all three cases, the PHF-PDSS facilitates bidirectional 
interactions between patients and health professionals toward improving adherence to treatment, 
patient empowerment of his/her health status and interfacing with informal and social care [8]. 
Finally, the professionals with research roles will be using the biomedical research platform 
(DHF-research), which has as data sources clinical information (through the Integrated Care 
Shared Knowledge Platform) as well as heterogeneous public and corporate sources of biomedical 
research data and the necessary tools to manage and process these data.  
Overall, an integrated care scenario provides support to organizational and technical 
interoperability between informal care and healthcare systems, which in turn feeds the DHF-
research with controlled and standardized clinical information for off-line research purposes. As 
an example, the Synergy-COPD project identified that oxidative stress may play a central role in 
COPD-complex and COPD-co-morb such that research professionals (with translational clinical 
and basic background) cooperate using the DHF-research to further explore other poorly known 
mechanisms and to generate combined biomarkers to assess novel therapeutic strategies in the 
clinical scenario. The DHF-research should be shaped to provide user-profiled functionalities 
such that research professionals with different profiles can make use of it, ultimately leading to 
the generation of novel rules that should feed in-place CDSS and PDSS.  
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3.2. Functional principles 
Based on the storyboard presented in the previous section we identified three key functional 
principles for the correct adoption of the DHF-research, namely: (i) data standardization strategies 
and open data policies, toward technical, syntactic and semantic interoperability between clinical 
data systems and biomedical research platforms, taking into account the privacy challenges of 
biomedical data sharing; (ii) profile-specific visual data mining functionalities covering the 
disparate needs and backgrounds of the DHF actors; and finally (iii) profile-specific environments 
supporting multi-scale predictive modelling and several forms of complex data analytics.      
3.3. Architectural principles  
The DHF-research architecture considers specific components to cover the need for 
organizational interoperability between research professionals working together over the same 
hypothesis and study design, as identified during the execution of Synergy-COPD. Moreover, 
general architectural principles are considered toward an open source solution with a rich set of 
functionalities empowering knowledge sharing, data querying and data analytics by means of a 
distributed, multi-layer, service oriented and ontology-driven architecture. 
3.4. Ethical and legal issues  
The evolving European legislation on health data transfer and security [10-13] was analyzed and 
taken into account for the design of each of the three components of the DHF (Figure 2) and 
facilitate the empowerment of patients to open their personal clinical data and derived studies to 
the scientific community. 
3.5. Deployment strategies and assessment  
The three building blocks of the DHF (Figure 2) have independent deployment strategies all of 
them with a stepwise approach. The DHF-research is in an early phase of the design of the proof-
of-concept generated from the lessons learnt in the Synergy-COPD project. Steps for a proper 
validation and identification of strategies for deployment were defined in the study. 
 
4. Description of the components and functionalities of the DHF-research 
The Synergy-COPD project prompted the identification of three pivotal layers of the DHF-
research, depicted in Figure 3, to support the research functionalities presented in subsection 3.1: 
i) a semi-automatic data mapping, consistency, and standardization layer; ii) an integrative 
knowledge management layer to gather and integrate clinical and biomedical knowledge coming 
from various healthcare electronic health systems and research information systems, as well as 
public databases; and, iii) to build on top of the knowledge management layer, a qualitative and 
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quantitative data exploitation layer with profile-specific visual data mining user-profiled 
interfaces. 
In the standardization layer displayed at the bottom of Figure 3, mapping, consistency, and 
standardization of clinical data will primarily rely on in-place health information exchange (HIE) 
infrastructures, where standard terminology (e.g. SNOMED-CT, SERAM, SEMN, LOINC, etc.), 
message encoding (e.g. HL7 2.x / 3.x, MLHIM, openEHR, ISO 13606, etc.), message routing and 
Security (e.g. IPSec, Audit trail, Node authentication, etc.) will be used. Moreover, the HIE 
infrastructure will provide the required technical and syntactic interoperability to support the 
information exchange requirements inherent to the logics of integrated care processes. 
Specifically, the DHF considers the use of an open source Integrated Care Shared Knowledge 
Platform designed to support the execution of ICS [6], which allows to normalize the process 
logics of ICS to a common legacy schema or data model. Similarly, standardization of biomedical 
research data and metadata (ISA-Tab [14], MIAME, etc.) is a required task before its connection 
to the knowledge management layer. This step will not be required for those public biomedical 
research data sources already standardized (e.g. Ensembl, Uniprot and KEGG). The ICS 
Knowledge Platform also considers integration with personal health folders, so that valuable data 
generated outside the boundaries of formal healthcare institutions, such as self-management 
questionnaires and applications, genomic and biomedical data, will be gathered and effectively 
incorporated into the formal care arena in the context of an integrated care service prescribing 
interactions with patients via the personal health folder. Ultimately, data normalization and 
curation is the responsibility of each data source before interfacing with the knowledge 
management system. However, each data source should agree with the knowledge management 
layer how to effectively ensure data normalization. Finally, each data source should make use of 
their specific front-end interfacing to effectively support the normalization and curation of already 
existing data, or to support the normalization of the data right at the data source (e.g. 
questionnaires, lab tests, etc.).    
Once all input data sources are properly encoded to a reduced set of common vocabularies and 
metadata schemas, and the exploitation rights granted, a knowledge management layer (as 
depicted in the middle of Figure 3) should allow the investigator to first integrate [15] and then 
to manage all of the above DHF-research information assets with easy to use and agile knowledge 
management graphical user web interfaces. The proprietary knowledge management solution 
assessed during the execution of the Synergy-COPD project [16] was based on the concept of 
knowledge as network by abstracting commonly used concepts and knowledge into objects and 
their relations. In addition, it bridged multiple sources and scales of knowledge and various 
deterministic and probabilistic models with a systems biology approach. Structuring explicit and 
implicit knowledge into these formal concepts enabled the use of existing well-defined 
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vocabularies (e.g. GO, ICD10) and standards (e.g. SBML, HL7) to couple true semantic 
integration (i.e. the mapping of equivalent meaning and objects) across all information types 
relevant in translational research with a flexible and extensible data model, ensuring robustness 
against structural changes in services and data, transparent usage, and low set-up and maintenance 
requirements. This knowledge management layer may also facilitate non-technological aspects of 
human and cultural dimensions to effectively enable information and knowledge sharing.  
 
Finally, this leads to the exploitation layer as displayed in the upper side of Figure 3 wherein 
potential use of profile-specific visual data exploitation portals are considered to support agile 
data querying at first and facilitating posterior data analytics. The latter will include a simulation 
environment capable of facilitating the user-friendly simulation of multi-scale predictive models, 
from common descriptive analytics to complex modelling approaches. 
The user-profiled portals ought to be primarily used by the two research actors of the DHF, the 
clinical and the basic scientist (Table1), allowing them, for example, to mine registered 
information to gain insight into mechanisms leading from health to disease transition and to study 
disease natural evolution, as well as interactions among diseases. Initial search, retrieval and R-
plugin based data mining methods integrated into the Synergy-COPD knowledge base (described 
in “The Synergy-COPD Knowledge Base: a data exploitation approach” chapter of the current 
monograph) enabled the retrieval of disease or case specific sub-networks by expert users but the 
validation showed that to enable application by clinical researchers a simplification of the user 
interface was required. To this end, the DHF-research considers the use of agile data querying 
interfaces such as those powered by the BioMart [17, 18] platform, used in the international cancer 
genome consortium (ICGC) Data Portal [19]. However, connectors to the R programming 
language should be available to accommodate for the needs of basic researchers having a 
bioinformatics profile. In addition, standard data analytic tools commonly used by clinical 
researchers should be made available within the exploitation layer. Moreover, such user-profiled 
portals may include links to new tools such as the Synergy-COPD multi-scale simulation 
environment (described in the “Simulation Environment and Graphical Visual Application: a 
COPD use-case” chapter of the current monograph), designed to enable the explorative execution 
of computational models. Ultimately, this data exploitation process should enable the translation 
of novel biomedical research outcomes into real clinical practice via generation of rules feeding 
novel CDSS. The latter (CDSS) should be embedded into novel clinical processes defined in 
terms of integrated care services, so closing the DHF continuous improvement circle. 
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5. Contributions of the DHF-research beyond the current state of the art  
We performed a thorough review of available ICT platforms that have been designed to support 
biomedical research with a systems approach [20-24]. Unfortunately, the reported information is 
fragmented and often insufficient to display a complete picture of each translational research 
platform. We review here the main characteristics of five state of the art initiatives considering 
the above DHF-research functional layers, namely: data standardization, knowledge management 
and data exploitation. 
Standardization layer - All five systems [20-25] support integration of data encoded using 
standard terminologies for clinical data entities (e.g. ICD9-CM, SNOMED, LOINC, etc.), but 
such an extensive use of standard terminologies is more difficult to accomplish in the context of 
basic biomedical research data adding extra efforts for the appropriate integration of data from 
different omics levels (e.g. Ensemble database, based on the BioMart project [17, 18]). 
A completely differentiating issue is the potential to interoperate with in-place clinical 
information, as such a functionality was only reported in STRIDE [20] that showed 
interoperability through a Health Information Exchange (HIE) platform via HL7 RIM messaging. 
It is of note that none of the five systems analysed [20-24] showed potential to interoperate with 
chronic care clinical information as described above.   
Knowledge management layer – All platforms [20-24] have reported the use of multiple standard 
terminologies for semantic integration of data from various sources, but none of them describes 
a complete set of tools for inference analyses as reported in detail in the “The Synergy-COPD 
Knowledge Base: a data exploitation approach” chapter of the current monograph. There is also 
a clear need to extend the Open Access framework into the clinical and personal perspective. 
Exploitation layer – All state of the art translational research platforms offer comprehensive sets 
of data mining and exploitation tools through unique user portals targeting all types of researchers 
roles, which necessarily limits acceptability and usability of the system that otherwise could 
greatly improve with a user-profiled approach. Moreover, current data exploration and data 
querying tools (such as the i2b2 [22] query tool) show potential to evolve toward more dynamic 
and agile data exploration capabilities.  
The review clearly identified the need for expanding the spectrum of users that should be 
achievable through a proper user-profiled orientation aiming at enhancing current user interfaces. 
An open source architecture with a service-oriented approach seems most adequate to build-up 
innovative business models allowing the continuous developments of enhanced functionalities 
based on sustainable costs-benefit ratios. Open Data schemas for all kind of data that the DHF 
integrates, the active role of patients and their empowerment to grant access to their own data, 
become crucial.  
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6. Discussion 
6.1. Contributions to a biomedical research scenario for predictive medicine  
The convergence of two major driving forces: i) current re-shaping of health systems seeking 
efficiencies through the alignment with the needs generated by chronic conditions, as discussed 
in detail in the “Synergy-COPD: a multidisciplinary approach for understanding and managing 
a chronic non-communicable disease” chapter of the current monograph and in [1]), and, ii) 
rapidly evolving perspectives of biomedical knowledge [26] is fostering the transition towards a 
mature 4P medicine scenario for chronic  patients. To the best of our knowledge, Synergy-COPD 
has provided one of the first relevant technological and biomedical contributions to this transition, 
using COPD and the analysis of co-morbidities as a use case. But most importantly, the project 
has identified important gaps, crucial unmet needs and strategic proposals that should help to 
consolidate the emerging scenario, specifically in the COPD case and in general to other disease 
areas. In this context, the conceptualization of the components of the DHF-research, as well as 
the proposals for its effective deployment together with the articulation of biomedical research 
with both formal and informal care, constitute one of the most significant outcomes of the project. 
The deployment of the concepts described in the current report should allow an efficient 
bidirectional articulation between biomedical research and both healthcare and environmental 
factors with impact on disease development and activity. By doing so, we can reasonably 
speculate that preventive strategies modulating the transition from health to disease, as well as 
disease progress, will be effectively implemented and adopted as part of the future conventional 
health promotion and healthcare scenario. Finally, it is expected that such future healthcare 
scenario may influence business innovation in pharmacological industry and healthcare business 
models by overcoming current fragmentation among informal care, healthcare and biomedical 
research, which shall have a high impact in shortening time to market for both drug development 
and drug repositioning. It may also help to foster novel synergies between pharmacological and 
non-pharmacological therapies.  
6.2. Challenges for deployment of the DHF  
The complexities of the deployment of the three-tier DHF, involving multiple interoperability 
levels (e.g. technological, organizational-cultural, etc.) and actors, are acknowledged.  
Informal Care - Previous experiences using Personal Health Systems [27] in general and with the 
PHF-PDSS [8] in particular have shown the potential of this tool serving three main purposes: i) 
empowering citizens and patients toward an active role in disease prevention and management, 
ii) favoring collection of structured information on environmental, sociological and behavioral 
factors influencing health status, as well as informal care interventions, and, iii) contributing to 
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organizational interoperability at health system level. However, practicalities limiting the 
extensive deployment and adoption of the PHF-PDSS have not been fully solved yet, but all of 
them seem actionable. These limiting factors encompass a wide spectrum of aspects, namely: 
technological approaches securing subject identification and data privacy, legal classification of 
the supporting systems as medical or non-medical devices, design of user-friendly interfaces and 
business models generating incentives for adoption, and also the interfacing between PHF-PDSS 
(informal care) and electronic health records (formal healthcare). It is of note, however, that all 
the above limiting factors are being addressed in several EU regions because the PHF-PDSS is 
becoming a pivotal component in the reshaping of the health system to face the challenge of 
chronic conditions.         
Formal care – There is increasing evidence that deployment of articulated integrated care services 
(ICS) covering the entire spectrum of patient severity is a good strategy to enhance health 
outcomes with cost containment  [28]. Different open ICT-platforms and strategies have been 
proposed to efficiently support the extensive deployment of ICS [28]. Implicit with those 
strategies are the integration of information collected through the PHF-PDSS (articulation with 
informal care) and clinical data normalization aiming at facilitating information sharing across 
healthcare tiers and among territories. Figure 3 in the current manuscript proposes such open 
ICT-platforms as a realistic option to integrate citizen information generated in either an informal 
or a formal care scenario, into biomedical research platforms (DHF-research). We acknowledge, 
however, that extensive deployment of those systems is still under development. A 
complementary approach to the proposal indicated in Figure 3 to facilitate short-term data 
integration into DHF-research could be the setting of highly curated clinical datasets specifically 
used for research purposes.    
Biomedical research – The deployment of DHF-research proposals displayed in Figure 3 require 
stepwise implementation strategies wherein two key aspects clearly emerge as main short-term 
priorities. Firstly, ICT developments aiming at generating user-friendly portals for clinicians 
devoted to translational research. A second element is the convergence of on-going developments 
in the area of knowledge management giving particular priority to the assessment of inter-
molecular (proteins, genes, or metabolites) interactions (physical or functional), transcriptional 
regulation and gene-disease association, that should foster the bridging between omics-generated 
knowledge and the clinical arena. Finally yet importantly, progresses in this area will be strongly 
associated to strategies fostering convergence of on-going ICT developments including both open 
and proprietary approaches. Finally, a relevant area is the design of innovative business models 
providing sustainability of biomedical research platforms beyond specific research and/or 
infrastructure projects that triggered the initial settings.      
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For all three DHF tiers, both legal and ethical aspects ensuring privacy and security of data 
transfer and management delineate a crucial area to be properly handled. Both data anonymization 
and encryption strategies have experienced a significant progress contributing to partially solving 
the problem. However, they show clear limitations in areas such as the management of genetic 
information wherein data anonymization is a challenge. In addition, the use of data for purposes 
other than the original data collection aims may generate limitations and activating communities 
of data donators for scientific purposes with a wider view than current practices is required. 
Clearly, evolving both legal frames and citizen cultural attitudes will be crucial to achieve a 
balance between social acceptance of anonymized data sharing together with reasonable levels of 
security and privacy of data transfer and management.  
6.3. Developments beyond the project lifetime 
We fully acknowledge that the current manuscript only displays basic lessons learnt during the 
Synergy-COPD project life span. Next immediate steps to be taken before the end of the project 
are twofold. First, to establish a focus group, including all actors, for the qualitative assessment 
of the current DHF proposal. The aim of the focus group should be to perform a qualitative 
assessment of the DHF fitness to transfer the biomedical research use case of Synergy-COPD to 
more general clinical research needs. Second, to generate structured interactions with well-known 
international experts in the three tiers of the DHF to prioritize specific steps of the deployment 
strategy, and, to plan collaborative interactions with selected on-going projects addressing similar 
aims.   
7. Conclusions 
The DHF is presented as a comprehensive and coherent ICT strategy supporting emerging 
requirements of applied systems medicine with novel interactions between informal care, formal 
healthcare and biomedical research. The current manuscript proposed ICT solutions for the three 
DHF tiers, extending more its biomedical research component, and stepwise strategies for 
effective deployment of the concept that should foster implementation of 4P medicine.     
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12. Figures 
 
 
Figure 1: The holistic approach intrinsic to system medicine of non-communicable diseases 
(NCDs) prompts the need for multilevel integration of heterogeneous patient information 
generated by different data sources, namely: environmental, clinical and biological data. 
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Figure 2: The concept of Digital Health Framework covers the different areas wherein 
information can be obtained and actions are taken: i) informal care, ii) formal care, and, 
iii) biomedical research. In this scenario, a personal health folder incorporating patient 
decision support systems (PDSS) might facilitate the incorporation of data coming from 
informal care into formal healthcare. In addition, biomedical research, referring to all 
research levels from clinical to basic research, should be shaped to provide user-profiled 
functionalities such that research professionals with different profiles can make use of 
clinical and biomedical knowledge from formal healthcare and heterogeneous biomedical 
research data sources, ultimately leading to the generation of novel rules that should feed 
in-place clinical decision support systems (CDSS). 
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Figure 3: DHF-research components and functionalities include semi-automatic data 
standardization approaches, data integration and knowledge management, profile-
specific visual data mining portals and user-profiled simulation environments (see text 
for further details). 
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13. Tables 
Table 1. Description of Actors and Roles in the Digital Health Framework 
Actors Roles Complexity ICT support 
Pa
tie
nt
 COPD-moderate 
Self-management 
PC 
PHF-PDSS COPD-complex 
PC&Specialist 
COPD-co-morb 
Primary Care 
Clinical 
Primary Care 
CDSS 
Specialized Care Secondary Care 
Clinical Scientist 
Research Academic DHF-research Basic Scientist 
 
COPD-moderate, patient with moderate functional impairment and low activity disease; COPD-
complex, patient with moderate to severe functional impairment with active disease both at 
pulmonary and systemic levels (skeletal muscle dysfunction/wasting); COPD-co-morb, patient 
with moderate functional impairment, high activity disease and co-morbid conditions (metabolic 
syndrome and cardiac failure);PC, Primary Care professionals (doctor & nurse); Specialized 
Care, Specialized Care (doctor&nurse); Clinical Scientist,  Translational research with clinical 
focus; Basic Scientist, Translational research with focus on basic sciences; PHF-PDSS, personal 
health folder including Patient Decision Support Systems; CDSS, Clinical Decision Support  
Systems; DHF-research, Digital Health Framework-Biomedical research platform.     
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Assessing the model of the oxygen pathway and mitochondrial ROS 
generation in health and in disease  
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Figure 6: Relationships between measured maximum O2 transport (VO2), y-axis; and, 
estimated cellular oxygenation (PmO2), x-axis, in COPD patients. The different symbols 
correspond to classical GOLD stages: squares, GOLD II; circles GOLD III; and, triangles, GOLD 
IV. The symbols connected with discontinuous lines correspond to the same patient (same 
VO2) with estimated PmO2 values corresponding to different mitochondrial oxidative capacities 
(Vmax values and VO2/Vmax ratios). For a given patient, the lower the VO2/Vmax ratio, the 
lower was the estimated overall exercising tissue PmO2. The colors correspond to the levels of 
mitochondrial ROS generation: green, mitochondrial ROS levels similar to those seen in healthy 
subjects; red, abnormally high mitochondrial ROS levels; and, violet, high ROS levels that 
persist after exercise withdrawal. The lower the PmO2, the higher were mitochondrial ROS 
levels.  
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Figure 7: Relationships between estimated average muscle maximum O2 transport (VO2), y-
axis; and, estimated average muscle cellular oxygenation (PmO2), x-axis, in COPD patients 
and healthy subjects. The different symbols correspond to classical GOLD stages: squares, 
GOLD II; circles GOLD III; and, triangles, GOLD IV. The colors correspond to the percent of 
exercising muscle estimated to generate abnormally high mitochondrial ROS generation: green 
(0%), yellow (0% - 24.9%), orange (25% - 49.9%), red (50% - 74.9%), and violet (75% - 
100%). The symbol size correspond to the subject measured body mass index (BMI): big 
symbols indicate subjects with normal BMI (>21 kg/m2) while small symbols indicate subjects 
with low BMI (≤ 21 kg/m2).  
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Figure 8: Estimated percent of exercising muscle predicted to generate abnormally high 
mitochondrial ROS generation (upper panel), estimated overall exercising muscle oxygenation 
(middle panel), and estimations for overall VO2max (lower panel). Simulation results for 
healthy subjects (C1-C9), COPD patients with normal body mass index (BMI) (N1-N12), and 
COPD patients with low BMI (L1-L6 both before and after a training period of 8 weeks. 
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Figure 9: Left-hand panel (a) shows that % of skeletal muscle (i.e. Vmax) producing high 
levels of ROS production for different disease groups (COPDN and COPDL denote COPD patients 
with normal and low Fat Free Mass Index respectively) and conditions (BT (Before training), 
AT (After training and D (After minus Before Training Difference)) is correlated with clinical 
measurements. In each comparison, the Pearson Correlation was computed, and the 
coefficient is provided in a percentage style. In the right-hand panel (b) Bonferroni-Adjusted 
P-values (in a percentage style) are shown. The MDA_Serum vs. %Vmax explained by ROS is 
the only bivariate that significantly correlates when the difference after and before training is 
considered (adjusted p-value <0.05). 
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Next steps for development of the DHF for biomedical research  
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Annex I 
 
??????????? ?????????????????????????????????????????????????
??????????????? ?????????? ????????????????????????????? ??????? ??????? ???????????
??????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????
?
Model 
parameter Description Units 
TOTALVMAX  Maximal mitochondrial oxygen consumption when oxygen is in excess (Vmax) of overall exercising muscle ml/min 
TOTALQ  Total Cardiac Output l/min 
TOTALP50  Total muscle partial oxygen pressure at which speed of mitochondrial oxygen consumption is half maximal  mm Hg 
EXS  Percent of TOTALQ that goes to exercising tissues (muscle) % 
VO2NEBP  Non-exercising body tissues oxygen uptake (VO2)   ml/min 
VCO2NEBP  Non-exercising body tissues carbon dioxide uptake (VCO2)  ml/min 
LOGSDVMAX  log SD Vmax (degree of muscle metabolism/perfusion heterogeneity) real number 
FIO2 Fractional Inspired Oxygen mm Hg 
TOTALVA  Total Alveolar Ventilation l/min (BTPS) 
TOTALDL  Total Lung Diffusion capacity ml/min/mmHg 
TOTALDM  Total Muscle Diffusion capacity ml/min/mmHg 
RQ CO2/O2 exchange ratio ratio 
PB  Atmospheric barometric pressure mm Hg 
HB  Hemoglobin mg/dl 
TEMP  body temperature degrees centigrade 
P50 O2 hemoglobin dissociation curve P50 mm Hg 
APH  PH of blood equilibrated with PCO2 of 30 mm Hg 
BPH  PH of blood equilibrated with PCO2 of 60 mm Hg 
SHUNT  cardiac shunt Percentage 
LOGSDQ log SD Q (degree of lung ventilation/perfusion heterogeneity real number 
QSKEW  Modal perfusion skew real number 
 
?
????????????????????????????????????????????????? ??????????????????????????????????
???????????? ?????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????? ???????? ??????????
????????? ????? ??? ????????? ?? ??????? ?????? ???????? ???????? ???? ??? ?? ???? ???????
????????????????????
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Model 
parameter Parameter estimation approach 
TOTALVMAX  20% higher than measured VO2max 
TOTALQ  Estimated for each subject, see Table I. 
TOTALP50  0.14 
EXS  80% for Controls and ((VO2max - VO2rest) / VO2max)*100 for COPD 
VO2NEBP  300 for Controls and measured for COPD 
VCO2NEBP  240 for Controls and 75% of measured VO2 for COPD 
LOGSDVMAX  0.1 
FIO2 0.21 
TOTALVA  Measured VE – (deadspace as (PaCO2-PaCO2exp)/PaCO2*tidal volume) 
TOTALDL  100 ml/min/mmHg. 
TOTALDM  Estimated for each subject, see Table I. 
RQ Measured 
PB  760 
HB  Measured 
TEMP  36.5 
P50 26.8 
APH  PH AND PaCO2 and use the Henderson Hasselbach nomogram. 
BPH  PH AND PaCO2 and use the Henderson Hasselbach nomogram. 
SHUNT  0 
LOGSDQ Estimated for each subject, see Table I. 
QSKEW  0 
  
?
??? ???????????????????????????? ???????????????????????????????? ????????? ??? ????????
????? ??? ?? ????????? ??? ????? ??? ?????????? ????????? ???? ??????????? ??? ????????? ??? ????
???????????? ???? ???? ????? ???? ????? ???? ???????? ??? ????? ?? ???? ????? ?????????? ?????
???????? ???????????????????????????????????????????????????????????????????????????
???????????????????????????????? ????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????? ????????????????????????????????????????????
?????????????????????????????????? ??? ??????????? ????? ????????????????????????????
???????? ????????? ??????? ?????? ?? ?????????? ??? ?????? ???? ?????? ?????? ???????? ????
????????? ???????? ????????????? ??? ?????? ?????? ??????????? ????? ???? ?????????? ??? ?????? ??
???????
?
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